Browse Month: June 2018

European Medicines Agency – Partners & Networks – Pharmaceutical industry, pharmaceutical industry marketing.#Pharmaceutical #industry #marketing

Pharmaceutical industry

The pharmaceutical industry is one of the European Medicines Agency’s (EMA) main stakeholders. Interacting with pharmaceutical companies has been a major part of EMA’s daily business since it began operating. These interactions are guided by a formal framework that rests on the principles of accountability, transparency and broad representation.

EMA routinely interacts with pharmaceutical companies through various channels, including:

  • overseeing the centralised authorisation procedure, whereby pharmaceutical companies apply for a single marketing authorisation valid throughout the European Union (EU);
  • providing scientific advice to companies to support research and development activities;
  • offering targeted information to micro, small and medium-sized enterprises (SMEs);
  • advising on compliance with EU regulatory requirements.

For certain activities, EMA charges pharmaceutical companies administrative fees. The bulk of the income from fees is redistributed among European Member States who provide the scientific expertise for assessing regulatory applications. For more information, see Fees payable to the EMA.

EMA also regularly discusses topics with industry representatives in the context of public health, including:

  • the implementation and operational impact of new legislation and scientific guidelines;
  • procedural and/or organisational developments at EMA, including policies such as those on transparency and public access to information;
  • the latest scientific advances in medicine.

EMA contact points for industry

The Corporate Stakeholders Department, set up in 2014, acts as a central contact point dedicated to consolidating, streamlining and coordinating EMA s relations and communication activities with pharmaceutical industry associations. Industry representatives can write to [email protected]

The dedicated SME office, established in 2005, addresses the specific needs of smaller pharmaceutical companies, with the aim of promoting innovation and development of new human and veterinary medicines.

Framework for interaction

The framework for interaction with industry stakeholders formalises and structures interactions with pharmaceutical industry associations active in the human and veterinary medicines. It defines the following objectives:

  • provide a platform to exchange views and promote dialogue with stakeholders on topics concerning medicines for human and veterinary use;
  • improve communication and provide efficient, targeted and timely information in a proactive manner;
  • enhance stakeholders understanding of the EU medicines regulatory framework and the role of the regulators and enrich the EMA s understanding of issues that are pertinent from the industry perspective for product development and licensing;
  • build on existing interactions between industry (including SMEs), academia and other stakeholders in the overall science, medicines, and healthcare arenas by co-operating with established networks and alliances;
  • increase transparency of stakeholders engaging with the EMA and report on the interaction.

The framework takes account of the general principles for stakeholder consultation outlined in the European Commission s staff working document on ‘Better Regulation Guidelines’, adopted in May 2015. EMA’s Management Board endorsed the framework for interaction in October 2015:

EMA will undertake regular surveys to monitor the implementation of this framework and will publish a report on the progress of interacting with industry stakeholders annually.

Pharmaceutical industry marketing 2016 Annual Report of EMA interactions with industry stakeholders

EMA publishes an annual report on its interactions with industry stakholders since 2015.

The framework is in line with EMA’s overarching framework for stakeholder relations management, which the EMA Management Board adopted in June 2016:

Eligibility criteria for involvement in EMA activities

Any industry organisation and association may register as an interested party by writing to [email protected] This allows them to receive information and notices of written consultations in selective areas of interest.

To be more directly involved in Agency activities, industry stakeholders will need to be deemed eligible for engaging in consultative dialogue and cooperating with Agency in specific areas.

Any not-for-profit industry organisation that fulfils the following eligibility criteria may apply:

  • legitimacy, with statutes registered in the EU or European Economic Area (EEA);
  • clear mission and objectives and an interest in human or veterinary medicines;
  • registered in the European Commission EU Transparency registry;
  • being representative of all its members and affiliations throughout the EU/EEA;
  • adequate structure.

For full details, see:

The eligibility criteria came into effect in January 2017. For the list of eligible organisations, see:

Compliance with the Agency s conflicts of interests policy continues to be pivotal to the Agency s accountability and governance for engagement with all of its stakeholders. Representatives of the pharmaceutical industry cannot be members of EMA s Management Board or be represented on any of EMA’s seven scientific committees.

Surveys

The report summarises the outcome of the 2015 EMA survey of industry stakeholders on centralised post-authorisation Type IB and Type II variations and PSUR procedures.





Bombshell Study Exposes Frightening Facts About Anti-Depressant Drugs – Pharmaceutical Companies – Collective Evolution, uk

Bombshell Study Exposes Frightening Facts About Anti-Depressant Drugs Pharmaceutical Companies

Uk pharmaceutical companies

The title of this article might give you the impression that my aim is to frighten you. I assure you it is not. The realities of the pharmaceutical industry are admittedly difficult to swallow, but this is important information given the fact that so many people are taking anti-depressant drugs. While these details may be disturbing, especially if you or someone you know takes anti-depressant drugs, it is important to move past the fear of information and really look at what has happened with the modern day medical industry and the pharmaceutical stranglehold that plagues it today.

“The medical profession is being bought by the pharmaceutical industry, not only in terms of the practice of medicine, but also in terms of teaching and research. The academic institutions of this country are allowing themselves to be the paid agents of the pharmaceutical industry. I think it’s disgraceful.” – (source)(source) Arnold Seymour Relman (1923-2014), Harvard Professor of Medicine and Former Editor-in-Chief of the New England Medical Journal

The most recent example of this kind of corruption comes from a study that was published last week in the British Medical Journal by researchers at the Nordic Cochrane Center in Copenhagen. The study showed that pharmaceutical companies were not disclosing all information regarding the results of their drug trials. Researchers looked at documents from 70 different double-blind, placebo-controlled trials of selective serotonin reuptake inhibitors (SSRI) and serotonin and norepinephrine reuptake inhibitors (SNRI) and found that the full extent of serious harm in clinical study reports went unreported. These are the reports sent to major health authorities like the U.S. Food and Drug Administration.

Tamang Sharma, a PhD student at Cochrane and lead author of the study, said:

We found that a lot of the appendices were often only available upon request to the authorities, and the authorities had never requested them. I m actually kind of scared about how bad the actual situation would be if we had the complete data. (source)

Joanna Moncrieff, a psychiatrist and researcher at University College London, elaborates:

[This study] confirms that the full degree of harm of antidepressants is not reported. They are not reported in the published literature, we know that and it appears that they are not properly reported in clinical study reports that go to the regulators and from the basis of decisions about licensing. (source)

Peter Gotzsche, a clinician researcher at Cochrane and the co-author of the study, actually tried to gain access to clinical trial reports almost a decade ago for anti-obesity pills. Unfortunately, the European Medicines Agency (EMA) denied them the reports:

They talked about commercial confidentiality although there was absolutely nothing in these reports that was commercially confidential. We explained that all this secrecy actually cost human lives, but they weren t interested in that at all. (source)

It took years of requests and complaints for this to happen and, while Gotzsche is pleased they were able to achieve this breakthrough, he reminds us that similar progress has yet to made in the United States. He went on to state that researchers need better access to data from clinical trials to conduct assessments unimpeded by industry influence:

It s deeply unethical when patients volunteer to benefit science and then we let drug companies decide that we cannot get access to the raw data. The testing of drugs should be a public enterprise. (source)

Moncrieff (quoted above) then goes on to express further concerns:

We really don t have good enough evidence that antidepressants are effective and we have increasing evidence that they can be harmful. So we need to go into reverse and stop this increasing trend of prescribing [them]. (source)

This Is Not The First Time

This is not the first time that pharmaceutical companies have been caught manipulating science in order to get antidepressants onto the shelves. It was only a couple of months ago that an independent review found that the commonly prescribed antidepressant drug Paxil (paroxetine) is not safe for teenagers, even though a large amount of literature had already suggested this previously. The 2001 drug trial that took place, funded by GlaxoSmithKline, found that these drugs were completely safe, and used that ‘science’ to market Paxil as safe for teenagers.

John Ioannidis, an epidemiologist at Stanford University School of Medicine and co-author of the study, is also the author of the most widely accessed article in the history of the Public Library of Science (PLoS), titled Why Most Published Research Findings Are False. In the report, he states that most current published research findings are false.” And this was more than 10 years ago — the situation has undeniably worsened in the interim.

This echoes the words of Dr. Richard Horton, the current Editor-In-Chief of one of the most reputable reviewed medical journals in the world:

The case against science is straightforward: much of the scientific literature, perhaps half, may simply be untrue. Afflicted by studies with small sample sizes, tiny effects, invalid exploratory analyses, and flagrant conflicts of interest, together with an obsession for pursuing fashionable trends of dubious importance, science has taken a turn towards darkness. (source)

The Editor in Chief of the New England Medical journal, which is also considered to be one of the best in the world, has made similar assertions:

It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgement of trusted physicians or authoritative medical guidelines. I take no pleasure in this conclusion, which I reached slowly and reluctantly over my two decades as an editor of the New England Journal of Medicine. (source)

A couple of years ago, Lucia Tomljenovic, a PhD in biochemistry and a senior postdoctoral fellow in UBC s Faculty of Medicine, uncovered documents that reveal vaccine manufacturers, pharmaceutical companies, and health authorities have known about multiple dangers associated with vaccines but chose to withhold them from the public. The documents were obtained from the UK Department of Health (DH) and the Joint Committee on Vaccination and Immunization (JCVI), who advise the Secretaries of State for Health in the UK about diseases preventable through immunizations. The JCVI made “continuous efforts to withhold critical data on severe adverse reactions and contraindications to vaccinations to both parents and health practitioners in order to reach overall vaccination rates. She goes on to explain that,

The transcripts of the JCBI meetings also show that some of the Committee members had extensive ties to pharmaceutical companies and that the JCVI frequently co-operated with vaccine manufactures on the strategies aimed at boosting vaccine uptake. Some of the meetings at which such controversial items were discussed were not intended to be publicly available, as the transcripts were only released later, through the Freedom of Information Act (FOI). These particular meetings are denoted in the transcripts as “commercial in confidence,” and reveal a clear and disturbing lack of transparency, as some of the information was removed from the text (i.e., the names of the participants) prior to transcript release under the FOI section at the JCVI website. (source)

Below is a clip taken from the One More Girl documentary, a film which looks at the Gardasil vaccine, a medicine designed to prevent Human Papillomavirus. In it, Dr. Peter Rost, MD, a former vice president of one of the largest pharmaceutical companies in the world (Pfizer), shares the truth about the ties between the medical and pharmaceutical industry.

Rost is a former vice president of Pfizer, and a whistleblower of the entire pharmaceutical industry in general. He is the author of The Whistleblower, Confessions of a Healthcare Hitman. Considering his work experience, it would be an understatement to say that he is an insider expert on big pharma marketing.

Sales news

Research news

Pharmaceutical industry articles

The state of trust

Roche s Future-proofing Healthcare event shows how the current model is a complicated one

Marketing news

Regulatory news

Pharmaceutical industry articles

Revolutionising how healthcare is delivered

The big technology shift sweeping the global connection of healthcare

Appointments

Press releases

PMHub Videos

Healthcare news

The Gallery

A visual showcase of agency work. Track down an agency from the image, track down your competitors’ work, search by product or therapy area to pull up, for example, cardiovascular campaigns. Click here for a portfolio of hundreds of campaign visuals – updated regularly – free for you to reference. Agencies – to add your work to The Gallery please contact us.

Pharmaceutical industry articles

Pharmaceutical industry articles

Pharmaceutical industry articles

Pharmaceutical industry articles

Pharmaceutical industry articles

MHRA joins Instagram as part of Yellow Card drive

UK medicines regulator follows in the footsteps of NICE in using the channel

Pharmaceutical industry articles

Annalisa Jenkins joins biomarker firm PlaqueTec as CEO

She arrives from US-based Dimension Therapeutics, where she was CEO

Pharmaceutical industry articles

Is AI changing the future of healthcare?

How technology is playing a big role in healthcare

Pharmaceutical industry articles

Proving the Strategic Value of Patients

Pharmaceutical industry articles

Tony de Fougerolles joins Evox Therapeutics as CEO

He succeeds Dr Per Lundin who stays at the firm as COO

Pharmaceutical industry articles

Teva launches personalised digital support for MS patients

Says its MS Care Programme is the first of its kind

Pharmaceutical industry articles

What value for innovation in an era dominated by affordability?

Pharma can collaborate but must be clear about its motives

Pharmaceutical industry articles

The Future of Marketing in Life Sciences: Is your function fit for purpose

Pharmaceutical industry articles

Do you want to see a magic trick?

Key points that drive behaviour change

Pharmaceutical industry articles





Home – Ibnsina Pharma, pharma brands.#Pharma #brands

Pharma brands

Pharma brands

Ibnsina Pharma is Egypt’s fastest-growing company in pharmaceutical distribution and related third party logistics more.

Our clients trust us to manage logistics and resolve challenges more.

Warehousing & Logistics

Ibnsina Pharma’s extensive experience as a pharmaceutical distributor allows us to manage the responsibility of warehousing and logistics for our suppliers to help them achieve their productivity goals. Our suppliers can confidently focus their time and energy on their core business, trusting us to handle storage and distribution.

Order Taking and Delivery

At Ibnsina Pharma, we rely on our team’s market expertise and rigorous ongoing research to identify and meet customer needs. All of our branches are open 15 hours a day and operate two shifts to provide customers with increased access to our team and ensure rapid response to all inquiries.

Distribution & Product Availability

Ibnsina Pharma’s core service is the distribution of pharmaceutical and cosmetics products from hundreds of manufacturers and suppliers to pharmacies and hospitals nationwide. We deftly manage logistics, inventory and delivery operations to ensure customer satisfaction — and manufacturer peace of mind.

Temperature-controlled Supply Chain

From supplier to warehouse to final destination, we guarantee the safe storage and delivery of temperature-sensitive products. Ibnsina Pharma’s employees receive extensive training in how to monitor temperature and take meaningful action to prevent product damage. Our team diligently manages all of the tasks required to prepare, store, transport and monitor these products, ensuring that they are kept in optimal conditions.

A Dedicated Sales Team

Our dedicated sales team works with suppliers to understand their needs, target clients with specific promotions and launch new products. Target audiences for products and promotions can be selected based on geography and other characteristics identified by the supplier and our sales team. We carefully monitor the success of telesales initiatives according to suppliers’ metrics or our own internal key performance indicators.

Importation and Packaging

In recent years, Ibnsina Pharma expanded its portfolio and become an official importer of various pharmaceutical products and medical devices. We collaborate with multinational organizations and major pharmaceutical companies worldwide to import safe, high-quality patented products.

Marketing Solutions

At Ibnsina Pharma, we go above and beyond to improve our suppliers’ bottom lines by helping to manage their brands and promote their products. Our marketing and sales teams work closely with their peers in our supplier companies to set marketing objectives and develop strategies for brand promotion. We use a variety of dynamic advertising tools to design and execute innovative marketing campaigns.

Manufactures

Ibnsina Pharma offers an effective distribution model that generates value and increases return on sales to a supplier network of more than 350 public, private and multinational pharmaceutical production companies in Egypt. With our carefully managed, state-of-the-art transportation system, we guarantee nationwide distribution of suppliers’ products to retail pharmacies, wholesalers and hospitals. Ibnsina Pharma is more than just a delivery service; we also offer our suppliers a variety of value-added services that make us the first choice among our competitors.

Importation and Packaging

In recent years, Ibnsina Pharma expanded its portfolio and become an official importer of various pharmaceutical products and medical devices. We collaborate with multinational organizations and major pharmaceutical companies worldwide to import safe, high-quality patented products. Our team is constantly pursuing new partnerships with reputable international suppliers to further meet demand in the Egyptian pharmaceuticals market and ensure that people have access to the products they need to thrive.

Our Customers

Ibnsina Pharma supplies pharmaceuticals and cosmetics to more than 35,000 private- and public-sector customers, including retail chains, independent pharmacies, wholesalers and institutional providers, through active participation in tenders. We rely on our highly efficient supply chain management system to deliver over 375,000 orders each month. >





European Medicines Agency – Pharmaceutical industry, pharmaceutical industry marketing.#Pharmaceutical #industry #marketing

Pharmaceutical industry

Pharmaceutical industry marketing

Information for you

On this page, you will find information on the Agency s activities that are most relevant to pharmaceutical industry, including news, and events.

You can contribute to the Agency s work by responding to public consultations.

Featured information

  • Pharmaceutical industry marketing

Survey on applying ‘big data’ in a regulatory setting

The joint Task Force on Big Data of the Heads of Medicines Agencies and EMA has launched a pharmaceutical industry survey on big data to help develop a big data strategy for the European medicines regulatory network. It seeks feedback on current experience, key challenges, applicability and added value of big data in the product lifecycle context. The survey is open until 20 October 2017. The task force will publish a summary report on its outcome. For any queries, please contact [email protected]

  • Pharmaceutical industry marketing

    Training webinar on preparation of PSURs

    EMA is holding a webinar on 22 September 2017 to identify key issues in the preparation of periodic safety assessment reports (PSURs) and share best practices on ways to address them. The webinar will be in the form of a question-and-answer (Q A) session and led by a joint panel of industry and regulators.

  • Pharmaceutical industry marketing

    Marketing authorisation holders will have access to the new EudraVigilance system as of 22 November 2017. EMA and the European Commission have agreed transitional arrangements to streamline their obligation to continuously monitor Eudravigilance and inform EMA and national competent authorities of validated signals they detect.

  • Pharmaceutical industry marketing

    EMA has published a report on its stakeholder workshop on the first annivesary of PRIME. The Agency has also published an infographic on the first 12 months of the PRIME scheme, which aims to enhance support for the development of medicines that target an unmet medical need. For more information, see PRIME: priority medicines.

  • Pharmaceutical industry marketing

    2016 annual report of interactions

    EMA has published the 2016 annual report on its interactions with industry stakholders. For more information, see Partners and networks: pharmaceutical industry.

  • Pharmaceutical industry marketing

    On 31 May 2017, EMA published a Q A providing further detail on location of establishment, following a notice to marketing authorisation holders of centrally authorised medicines to remind them of their legal obligations in preparation for Brexit. For more information, see UK s withdrawal from EU.

  • Pharmaceutical industry marketing

    Common European Single Submission Portal

    EMA and Heads of Medicines Agencies (HMA) have published a statement of intent on replacing electronic application forms (eAFs) for human and veterinary medicines applications by a Common European Single Submission Portal (CESSP). The first version will cover initial marketing authorisation and extension applications, and should be available by Q1 2018. At a later stage CESSP will replace all other eAFs for variation and renewal applications. It will eventually integrate HMA’s Common European Submission Platform (CESP) and EMA s eSubmission Gateway into a single system.

  • Pharmaceutical industry marketing

    Early development advice services

    EMA offers a range of advisory services to companies working in research and development of medicines. EMA has developed a consolidated list of available guidance and opportunities for interaction in the development phase of a human medicinal product. For veterinary medicines, specific early development services include scientific advice, the Innovation Task Force and veterinary pre-submission meetings.

  • Pharmaceutical industry marketing

    Submission dates (human and veterinary)

    See the submission dates and procedural timetables for human medicines, including marketing-authorisation applications, extensions, variations and referrals and the submission dates for veterinary medicines, including maximum residue limits procedures.





  • Pharmaceutical Contract and Pharmaceutical Manufacturing Company in India – Piramal Pharma Solutions, pharma company list.#Pharma

    pharma company list

    Pharma company list

    Pharma company list

    • Pharma company list
    • Pharma company list
    • Pharma company list

    Pharma company list

    Pharma company list

    Pharma company list

    Pharma company list

    Pharma company list

  • Pharma company list

    Pharma company list

    Pharma company list

    Pharma company list

    Pharma company list

    Pharma company list

  • Pharma company list

    Pharma company list

    Pharma company list

    Pharma company list

    Pharma company list

    Pharma company list

  • Pharma company list

    Pharma company list

    Pharma company list

    Pharma company list

    Pharma company list

    Pharma company list





  • Pharma TechOps 2017, pharma career.#Pharma #career

    FROM A FIRE FIGHTER MENTALITY TO A FORMULA 1 SPIRIT

    November 30 December 01, 2017 | Maritim proArte Hotel Berlin, Germany

    The Pharma TechOps Sessions

    The 2.5-day event is a unique combination of

    Inspirational keynotes Panel discussions

    Well moderated, interactive World Caf sessions

    Challenge Your Peers roundtables

    Be part of our exclusive platform to explore various business models, case studies actions to increase profitability and identify missing gaps that hide opportunities business chances for your challenges.

    The 2.5-day event is a unique combination of

    Inspirational keynotes Panel discussions

    Well moderated, interactive World Caf sessions

    Challenge Your Peers roundtables

    Be part of our exclusive platform to explore various business models, case studies actions to increase profitability and identify missing gaps that hide opportunities business chances for your challenges.

    Hundreds of maintenance & engineering projects and technology budgets under the same roof

    Get involved at the event as a Business Partner. For our event partners it is a one-stop-shop opportunity to promote thought-leadership and get face-to-face with over 100 key prospects.

    Pharma TechOps offers the best in class opportunity to introduce yourself as a thought leader to pharma professionals involved in maintenance and plant availability projects.

    Get involved at the event as a Business Partner. For our event partners it is a one-stop-shop opportunity to promote thought-leadership and get face-to-face with over 100 key prospects.

    Pharma TechOps offers the best in class opportunity to introduce yourself as a thought leader to pharma professionals involved in maintenance and plant availability projects.

    Highlight Speakers 2017

    Pharma career

    Pharma career

    Head of Global Manufacturing

    The Grünenthal Group

    Pharma career

    Pharma career

    Dr. Dieter Peters, Head of Global Manufacturing, The Grünenthal Group

    Dieter Peters, born 1956, received his PHD at the University of Dortmund in chemistry. From 1986 to 1996 he worked at Hoechst AG and from 1996 to 2002 at Celanese AG. In 2002 he joined the Gr nenthal Group Switzerland as Managing Director. From October 2011 to May 2017 he worked as Head of Global Product Supply and since May 2017 he is the Head of Global Manufacturing. He is an expert in turn arounds and restructuring.

    Challenge Your Peers

    Operational Excellence in Pharma Manufacturing Technology, Capacity and Availability management in manufacturing can provide significant advantages to business – HOW?

    • How can pharma catch up with state of the art management processes, employee involvement and continuous improvement culture that are daily routine in other industries? (Deliverables: Key must haves to accomplish that)
    • What are you doing in your company to catch up and which benefits have you realized? (Deliverables: Changes you have implemented and your measurable business advantages)
    • What are you doing to discover the true waste in your processes and become more productive and service oriented? (Deliverables: What barriers did you overcome, what did you find which wasn t so obvious, what are your most memorable wins)
    • How do you work with regulatory requirements and departments to realize innovation and mitigate risk? (Deliverables: Examples of change and cooperation with regulatory colleagues to make it happen)
    • Who is driving innovation and change in your company what is your role? (Deliverable: Examples to make an Innovation out of an invention)
    • How do you efficiently connect R D and Manufacturing? (Deliverables: Example processes and Best Practice process)
    • How do you integrate external manufacturing in established and innovative products manufacturing? (Deliverables: Role model examples and lessons learned from challenged cooperation)

    The Gr nenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation.

    Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a 2 billion company.

    We are a fully integrated research development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R D above the industrial average, we are strongly committed to innovation.

    Gr nenthal is an independent, family-owned company headquartered in Aachen, Germany. We are present in 32 countries with affiliates in Europe, Latin America and the US. Our products are sold in more than 155 countries and approx. 5,500 employees are working for the Gr nenthal Group worldwide. In 2016, Gr nenthal achieved revenues of approx. 1.4 bn.





    PCD Pharma Companies in India, Pharma Franchise Comapny India – Fossil Remedies, pharma company list.#Pharma

    Welcome to Fossil Remedies – One of The Best Pharma Franchise Company in India

    Fossil Remedies is leading manufacturers and marketers of Pharmaceutical formulations

    and recognized in the market, due to our ability to manufacture, export and supply a diverse and qualitative range of Pharma Products like Tablets, Capsules, OralLiquids, Dry Syrup, Powders, Injections, Sachet and Effervescent. To formulate our range, we use hygienic ingredients that we have sourced from the authentic and reliable vendors of the market who hold rich expertise in this domain. We give franchise/ monopoly on PCD. Fossil is well known as PCD Pharma Franchise Company in Ahmedabad, Gujarat, India.

    Fossil Remedies spread there business at the unrepresented areas through appointment of new franchise / distributors / sole distributors / pcd franchise / monopoly.

    Fossil have installed latest and advanced machines to formulate our range as per the industrial standards (GMP Certified). With a worthy experience, we provide a wide range of Pharmaceutical Bulk Drugs. These are formulated using superior quality of ingredients at the manufacturers end. We have an expert team of quality controllers, which is responsible to stringently monitor complete ongoing business at each and every stage right from the sourcing of products till the final dispatch at the clients end

    We always provide highest quality medicine for all and maintain a leading position in the global markets. We rely on the highest quality standards in achieving all of our goals. Fossil has immensely promoted the culture of WHO GMP throughout the company.

    Our Quality Assurance Department monitors all stages of production, analysis, and warehousing. They managed by qualified personnel, constantly examines quality considerations – performing systematic sampling and testing at every stage from raw materials, through each procedure of intermediate and finished pharmaceutical formulations.

    Individuals who are decently experienced in Pharma Marketing needs to do their own business in pharma. We invite them to appreciate the complete syndication rights and build themselves.

    We Offer PCD Pharma Franchise based wholesalers for extensive variety of items all through India. Genuine, committed and experienced individual are welcome for sole Marketing and Distribution rights.

    We are searching for District savvy PCD Pharma Franchise in taking after State:





    Jamp pharma#Jamp #pharma

    New products

    • Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    Jamp pharma

    JAMP- Bezafibrate

    Once again, JAMP Pharma expands its product family !

    • Generic equivalent of Bezalip
    • Lipid metabolim regulator
    • Available in blisters of 30 and bottle of 30 tablets

    For more information, contact your JAMP Pharma sales representative or our Customer Service at 1 866 399-9091.





    PCD Pharma Franchise Company In Chandigarh, Innovexia Life Sciences, pharma company list.#Pharma #company #list

    Welcome To Innovexia Life Sciences

    Best PCD Pharma Franchise Company in Chandigarh – The Innovexia Life Sciences is Chandigarh based pharma company with the wide spectrum of products ranging from the advanced antibiotics, a range of health care products: Tablets, Capsules, Injectables, Syrups, Protein Powder, Ointments and other Pharma Products. These are manufactured from high-grade chemicals, protein, vitamin, minerals and other material in the accurate composition. The ingredients are procured from faithful vendors to ensure its international quality standard. Each brand is value added for better patient benefits and compliance. We are top PCD pharma franchise company that is offering top pharma franchise in Chandigarh and other top states of India.

    Innovexia Life Sciences Pvt Ltd is one of India’s most respected pharmaceutical companies and is committed to delivering better health through superior products. By combining strategic research and expert industry knowledge, Innovexia aims to transform itself into a global pharmaceutical drug company. So innovexia come in list of top pharma franchise companies of India

    Innovexia Life Sciences is established in the year 2011 and is engaged in manufacturer, supplier, trader and distributor quality assured the range of Pharmaceutical Medicines. Innovexia Life Sciences is best pharma franchise company that markets the wide range of medicines – some of them are life savers, while others improve the quality of life for millions of people. Innovexia Life Sciences is among leading manufacturer and supplier of pharmaceutical formulations offering a broad gamut of Pharmaceutical Tablets, Capsules, Psychiatry Tablets, and Injections. The people who will drive this organization are picked from the best places and all of them bring in the rich knowledge of the Indian Pharmaceutical market and the best work practices for a great success. So we are top pharma company that is offering PCD Pharma Franchise in Chandigarh

    We are looking for young and dynamic people to join us as business associates and to be part of this growing company. Innovexia continues to maintain a leadership position in the domestic contract manufacturing sphere for the pharmaceutical industry and has made significant inroads in its area of operation. So if you are looking Best pharma franchise company then Innovexia life Sciences is the best option for you.





    Top 10 POISONS most Americans eat or drink EVERY day –, raptor pharma.#Raptor #pharma

    Top 10 POISONS most Americans eat or drink EVERY day

    Wednesday, October 25, 2017 by: S.D. Wells

    Raptor pharma

    (Natural News) If you accidentally sprayed roach killer or weed killer on your fruit, you would probably rush to wash it off, knowing it would make you sick if you ate it, now or later (in fact you would probably discard the produce entirely). If you put poisonous rat baits or pest-killing food pellets under your home, you would certainly make sure your dog or cat couldn t get to them, knowing what would happen if they did. Heck, that s just common sense and responsible living. Yet the search for the cure for cancer and Alzheimer s disease marches on, while tens of millions of Americans eat food and drink beverages that are loaded with weed killer, bug killer, and industrial toxins that warp our cells, destroy our immune systems and incapacitate our cognitive abilities.

    Over time, conventional American food literally deconstructs our genetics, creating and perpetuating health disasters for which the medical and scientific communities just can t seem to prevent or solve. Maybe that s because they re all the ones making their fortunes off the problem.

    Mark these words: No chemical medicine will ever prevent or cure the health problems that chemicals in food, drinks and medicine are causing. There are no pain killers, diabetes medicines, chemotherapy drugs or anti-anxiety medications that can fix your brain, heart, liver, kidneys and pancreas when the very CAUSE of the malfunctions is found in synthetics and carcinogens that are being consumed daily. When you eat GM corn and soy daily, take baby aspirin for your heart, eat antacids for your indigestion, make your coffee and tea with tap water, drink out of plastic bottles and eat fried foods made with processed oils, you re asking for chronic health disaster to come your way – in fact, you re inviting it into your life.

    Take a close look at the 10 most popular poisons most Americans eat or drink EVERY single day

    #1. Insecticides Dioxin and 2,4-D: Corporations like Monsanto, Bayer, Dupont, Dow, Syngenta, Cargill and BASF do NOT care about human life or health. They are in business to make money, kill bugs and kill weeds – period. Most chemical insecticides utilized on American crops are toxic to humans and cause cancer and dementia.

    #2. Glyphosate (and other toxic herbicides) Roundup, the world s most popular weed killer, contains 50 percent glyphosate, commonly used on fiber and wheat as a drying agent before processing begins in the silos. Many U.S. staple crops are embedded with glyphosate in their genetic makeup as biotechnology firms create food that contains poison, so that more poison can be sprayed on the plants without killing them. (Doesn t matter to them if it kills humans, bees or farm animals.)

    #3. Sodium Fluoride Industrial chemical byproduct of industries in China imported to the USA as an insecticide and dripped into tap water with the unsubstantiated claim that it s good for building strong teeth and preventing cavities.

    #4. Bleach  Most white foods are bleached white. Bleach causes pancreatic cancer and bladder cancer – two of the toughest cancers to survive. Consider never eating white bread, white rice (except basmati), white flour, white pasta or white sugar.

    #5. Bisphenol A (BPA) В This poison is found in many plastic containers and canned foods.

    #6. Benzene a petrochemical and constituent of crude oil colorless and highly flammable commonly used in sodas.

    #7. Hexane a solvent and chemical cleaning agent used in the processing of canola oil and soy oil (it s a cheap way to separate the oil from the protein) commonly found in infant formulas, veggie burgers, fruit and nut bars, protein drinks.

    #8. PCBs chlorine compound often found in salmon and canned sardines.

    #9. Aspartame The most popular artificial sweetener on earth that causes weight gain. The patent confirms it is the excrement of genetically modified bacteria. That s just nasty! Aspartame is known to cross the blood-brain barrier, so the brain’s cells are bombarded, and the result is neural cell damage and eventually cell death – which can lead to serious brain damage. Many of the symptoms of aspartame poisoning mimic the symptoms of multiple sclerosis (MS) and even dementia, like Alzheimer’s.

    #10. Ammonia The conventional U.S. meat industry thrives on one theory: If it doesn t make you sick or kill you within 24 hours, then it s safe. Most conventional red meat is ammonia-treated (and bleached) to kill theВ E. coliВ and then dyed back pink, like with hamburger and steak, to look attractive in the butcher s window.

    Change what you eat – change your life Real doctors literally PRESCRIBE organic plant-based foods for disease treatment

    Alternative medicine is blasted by the medical community because it finds and eliminates the root causes of most diseases and disorders which, for the most part, makes doctors less money. Without surgery, chemotherapy and expensive pharmaceuticals, most M.D.s and oncologists couldn t live the lavish lifestyle they do right now. If you want your health to be organic and sustainable, doesn t it make sense that everything you eat and take as medicine be just that?

    The solution for ideal health free of disease and disorder is not as complex as you may think. Begin by eliminating the most common toxins from your daily intake. You will notice a difference immediately in how you feel, your energy level and your clearer thinking. You may even realize after a few weeks or months that the cure for most diseases and disorders exists in an organic, plant-based food regimen, and you will be absolutely and positively correct.

    What s your doctor prescribing for you – chemicals or organics? You better start asking the right questions if you want the right answers. Here s some valuable knowledge from a doctor that you ll always remember after watching.

    Sources for this article include:





    Pharmaceutical price regulation scheme 2014, uk pharmaceutical companies.#Uk #pharmaceutical #companies

    Pharmaceutical price regulation scheme 2014

    A 5-year voluntary scheme agreed between government and the Association of the British Pharmaceutical Industry effective from 1 January 2014.

    Documents

    Uk pharmaceutical companies

    The pharmaceutical price regulation scheme 2014

    PDF , 1.2MB , 133 pages

    Uk pharmaceutical companies

    Addendum to the 2014 pharmaceutical price regulation scheme

    PDF , 129KB , 4 pages

    Details

    The 2014 Pharmaceutical Price Regulation Scheme (PPRS ) will provide assurance on almost all of the branded medicines bill for the NHS. The bill will stay flat over the first 2 years of the scheme and will grow slowly after that. The industry will make payments to the Department of Health (DH ) if NHS spending on branded medicines exceeds the allowed growth rate.

    The PPRS is a voluntary agreement to control the prices of branded drugs sold to the NHS. It is negotiated between DH , acting on behalf of the UK government and Northern Ireland, and the branded pharmaceutical industry, represented by the ABPI .

    The ABPI and DH agreed in August 2015 to amend the 2014 Pharmaceutical Price Regulation Scheme (PPRS ) to clarify the way in which spending under the Cancer Drugs Fund is treated by the Scheme.

    Under the agreement, the department and the ABPI sought to protect the interests of all NHS patients, including patients who benefit from the Cancer Drugs Fund, while recognising the need to clarify Cancer Drugs Fund spending within the PPRS .

    The parties have now agreed to a further technical amendment, which does not alter the agreed amounts of CDF spend which will be subject to the PPRS Payments System. It is aimed at securing greater stability and predictability in payment percentages for the duration of the scheme.





    Pharmaceutical Contract and Pharmaceutical Manufacturing Company in India – Piramal Pharma Solutions, pharmaceutical manufacturing company.#Pharmaceutical

    pharmaceutical manufacturing company

    Pharmaceutical manufacturing company

    Pharmaceutical manufacturing company

    • Pharmaceutical manufacturing company
    • Pharmaceutical manufacturing company
    • Pharmaceutical manufacturing company

    Pharmaceutical manufacturing company

    Pharmaceutical manufacturing company

    Pharmaceutical manufacturing company

    Pharmaceutical manufacturing company

    Pharmaceutical manufacturing company

  • Pharmaceutical manufacturing company

    Pharmaceutical manufacturing company

    Pharmaceutical manufacturing company

    Pharmaceutical manufacturing company

    Pharmaceutical manufacturing company

    Pharmaceutical manufacturing company

  • Pharmaceutical manufacturing company

    Pharmaceutical manufacturing company

    Pharmaceutical manufacturing company

    Pharmaceutical manufacturing company

    Pharmaceutical manufacturing company

    Pharmaceutical manufacturing company

  • Pharmaceutical manufacturing company

    Pharmaceutical manufacturing company

    Pharmaceutical manufacturing company

    Pharmaceutical manufacturing company

    Pharmaceutical manufacturing company

    Pharmaceutical manufacturing company





  • Biotech Industry, Biotech News, Biotechnology Articles, fda and pharmaceutical industry.#Fda #and #pharmaceutical #industry

    fda and pharmaceutical industry

    Certain microRNAs in the saliva of concussion patients could help gauge the severity of concussions and predict the length of concussion symptoms.

    Fda and pharmaceutical industry

    Toxicity knocks Ardelyx s hyperkalemia hopes back to preclinic

    Unexpected side effects have spelled the end for Ardelyx’s drug candidate to treat elevated potassium levels in the blood, which was in phase 3 testing.

    Fda and pharmaceutical industry

    Cytokinetics cans lead drug after phase 3 ALS wipeout

    Cytokinetics canned tirasemtiv after it failed to beat placebo against the primary endpoint or any of the secondary goals in an ALS trial.

    Fda and pharmaceutical industry

    Step Pharma bags cash for CTPS1 autoimmune R D drive

    The $17 million financing equips the lean French biotech to prepare its CTPS1 inhibitors for clinical testing in autoimmune disorders.

    Fda and pharmaceutical industry

    PTK6 blocker could treat or even prevent ER+ breast cancer metastasis

    The enzyme PTK6 could be targeted to quell the growth of estrogen receptor-positive breast cancer, a common form of the disease.

    Fda and pharmaceutical industry

    Amsterdam beats out Milan to host EMA

    After tying with Milan in a third round of voting, Amsterdam will be the new home of the European Medicines Agency.

    Fda and pharmaceutical industry

    LivaNova to offload Cardiac Rhythm unit for $190M

    LivaNova will sell its Cardiac Rhythm Management business to its joint venture partner, MicroPort Scientific.

    Fda and pharmaceutical industry

    DBV climbs as peanut allergy safety data come in clean

    Shares in DBV rose on the back of the data, going a little way to erasing the big drop it suffered after missing its primary efficacy endpoint.

    Fda and pharmaceutical industry





    AMMAN PHARMACEUTICAL INDUSTRIES, biggest pharma companies.#Biggest #pharma #companies

    biggest pharma companies

    Biggest pharma companies

    Biggest pharma companies

    Biggest pharma companies

    Biggest pharma companies

    Biggest pharma companies

    Biggest pharma companies

    Biggest pharma companies

    Biggest pharma companies

    Biggest pharma companies

    Biggest pharma companies

    Biggest pharma companies

    Biggest pharma companies

    Strategy

    Production Facilities

    Board Of Directors

    Board Of Directors Read more

    Biggest pharma companies

    Biggest pharma companies

    Biggest pharma companies

    Biggest pharma companies

    Explore our map to discover where we operate and to find contact details for our offices across the globe.

    Biggest pharma companies

    Biggest pharma companies

    Biggest pharma companies

    Biggest pharma companies

    Biggest pharma companies





    Pharmaceutical Industry, Indian Pharma Industry, Pharmaceutical Industry, Pharma Industry Overview, fda and pharmaceutical industry.#Fda #and

    Indian Pharmaceutical Industry

    “The Indian pharmaceutical industry is a success story providing employment for millions and ensuring that essential drugs at affordable prices are available to the vast population of this sub-continent.”

    The Indian Pharmaceutical Industry today is in the front rank of India s science-based industries with wide ranging capabilities in the complex field of drug manufacture and technology. It ranks very high in the third world, in terms of technology, quality and range of medicines manufactured. From simple headache pills to sophisticated antibiotics and complex cardiac compounds, almost every type of medicine is now made indigenously.

    Playing a key role in promoting and sustaining development in the vital field of medicines, Indian Pharma Industry boasts of quality producers and many units approved by regulatory authorities in USA and UK. International companies associated with this sector have stimulated, assisted and spearheaded this dynamic development in the past 53 years and helped to put India on the pharmaceutical map of the world.

    Growth Scenario in 2010

    India’s pharmaceutical industry is now the third largest in the world in terms of volume. Its rank is 14th in terms of value. Between September 2008 and September 2009, the total turnover of India’s pharmaceuticals industry was US$ 21.04 billion. The domestic market was worth US$ 12.26 billion. This was reported by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. As per a report by IMS Health India, the Indian pharmaceutical market reached US$ 10.04 billion in size in July 2010. A highly organized sector, the Indian Pharma Industry is estimated to be worth $ 4.5 billion, growing at about 8 to 9 percent annually. Know more out this in our article on Indian Pharmaceutical Industry- Future Trends Also check out Pharmaceutical Market Trends 2010

    Leading Pharmaceutical Companies

    In the domestic market, Cipla retained its leadership position with 5.27 per cent share. Ranbaxy followed next. The highest growth was for Mankind Pharma (37.2%). Other leading companies in the Indian pharma market in 2010 are:

    • Sun Pharma (25.7%)
    • Abbott (25%)
    • Zydus Cadila (24.1%)
    • Alkem Laboratories (23.3%)
    • Pfizer (23.6 %)
    • GSK India (19%)
    • Piramal Healthcare (18.6 %)
    • Lupin (18.8 %)

    For details check out List of Top 10 Pharmaceutical Companies in India

    Future Prospects

    The Indian pharmaceuticals market is expected to reach US$ 55 billion in 2020 from US$ 12.6 billion in 2009. This was stated in a report title India Pharma 2020: Propelling access and acceptance, realising true potential by McKinsey Company. In the same report, it was also mentioned that in an aggressive growth scenario, the pharma market has the further potential to reach US$ 70 billion by 2020

    Due to increase in the population of high income group, there is every likelihood that they will open a potential US$ 8 billion market for multinational companies selling costly drugs by 2015. This was estimated in a report by Ernst Young. The domestic pharma market is estimated to touch US$ 20 billion by 2015. The healthcare market in India to reach US$ 31.59 billion by 2020. The sale of all types of pharmaceutical drugs and medicines in the country stands at US$ 9.61 billion, which is expected to reach around US$ 19.22 billion by 2012. Thus India would really become a lucrative destination for clinical trials for global giants.

    Characteristics of Indian Pharmaceutical Industry

    The Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units. It has expanded drastically in the last two decades. The leading 250 pharmaceutical companies control 70% of the market with market leader holding nearly 7% of the market share. It is an extremely fragmented market with severe price competition and government price control.

    Why India?

    Competent workforce: India has a pool of personnel with high managerial and technical competence as also skilled workforce. It has an educated work force and English is commonly used. Professional services are easily available.

    Steps to strengthen the Industry

    Indian companies need to attain the right product-mix for sustained future growth. Core competencies will play an important role in determining the future of many Indian pharmaceutical companies in the post product-patent regime after 2005. Indian companies, in an effort to consolidate their position, will have to increasingly look at merger and acquisition options of either companies or products. This would help them to offset loss of new product options, improve their R D efforts and improve distribution to penetrate markets.





    Ciba pharmaceuticals, ciba pharmaceuticals.#Ciba #pharmaceuticals

    About CIBA VISION

    With a focus on innovation, quality and strong partnerships with eye care professionals, CIBA VISION is a global leader in the research, development and manufacturing of contact lenses and lens care products. CIBA VISION shares the eye care professional’s passion for healthy vision and dedication to improving the quality of patients’ lives around the world. Headquartered in Atlanta, Georgia, we provide solutions that fit the lifestyles, preferences and needs of people in more than 70 countries around the world.

    CIBA VISION is committed to innovation – exploring new materials and devices that continue to yield eye care breakthroughs. Our research development (R D) efforts have produced lenses such as O2OPTIX™, high-oxygen, breathable lenses for healthy eyes; NIGHT DAY®, high-oxygen extended wear lenses that can be worn for up to 30 continuous nights; and Focus® DAILIES®, daily disposable contact lenses.

    Additionally, we are the leading international provider of cosmetic contact lenses to change and enhance eye color. CIBA VISION FreshLook® lenses enable you to change, enhance or illuminate your eyes. CIBA VISION offers the widest variety of colors, modalities and cosmetic contact lens styles – more than 85 combinations in all – of any contact lens manufacturer.

    In lens care, CIBA VISION has pioneered many products, such as Aquify® 5 Minutes Multi-Purpose Solution and Clear Care® (also marketed as SOLO-care Aqua™ and AOSept Plus™ respectively outside the U.S.).

    Parent Company

    As the eye care unit of Novartis AG, CIBA VISION benefits from the strengths and resources of one of the largest healthcare companies in the world. Novartis is a world leader in healthcare, with core businesses in pharmaceuticals, consumer health, pediatrics, eye care and animal health.

    Headquartered in Basel, Switzerland, Novartis companies employ approximately 80,000 people and operate in more than 140 countries around the world. In 2005, the Group’s businesses achieved collective sales of approximately USD 32.2 billion and a net income of approximately USD 6.1 billion. Together, CIBA VISION and Novartis share a vision of developing new products that bring new hope and improve the lives of people around the globe.





    Biotech Industry, Biotech News, Biotechnology Articles, fda and pharmaceutical industry.#Fda #and #pharmaceutical #industry

    fda and pharmaceutical industry

    Certain microRNAs in the saliva of concussion patients could help gauge the severity of concussions and predict the length of concussion symptoms.

    Fda and pharmaceutical industry

    Toxicity knocks Ardelyx s hyperkalemia hopes back to preclinic

    Unexpected side effects have spelled the end for Ardelyx’s drug candidate to treat elevated potassium levels in the blood, which was in phase 3 testing.

    Fda and pharmaceutical industry

    Cytokinetics cans lead drug after phase 3 ALS wipeout

    Cytokinetics canned tirasemtiv after it failed to beat placebo against the primary endpoint or any of the secondary goals in an ALS trial.

    Fda and pharmaceutical industry

    Step Pharma bags cash for CTPS1 autoimmune R D drive

    The $17 million financing equips the lean French biotech to prepare its CTPS1 inhibitors for clinical testing in autoimmune disorders.

    Fda and pharmaceutical industry

    PTK6 blocker could treat or even prevent ER+ breast cancer metastasis

    The enzyme PTK6 could be targeted to quell the growth of estrogen receptor-positive breast cancer, a common form of the disease.

    Fda and pharmaceutical industry

    Amsterdam beats out Milan to host EMA

    After tying with Milan in a third round of voting, Amsterdam will be the new home of the European Medicines Agency.

    Fda and pharmaceutical industry

    LivaNova to offload Cardiac Rhythm unit for $190M

    LivaNova will sell its Cardiac Rhythm Management business to its joint venture partner, MicroPort Scientific.

    Fda and pharmaceutical industry

    DBV climbs as peanut allergy safety data come in clean

    Shares in DBV rose on the back of the data, going a little way to erasing the big drop it suffered after missing its primary efficacy endpoint.

    Fda and pharmaceutical industry





    Pharma TechOps 2017, biggest pharma companies.#Biggest #pharma #companies

    FROM A FIRE FIGHTER MENTALITY TO A FORMULA 1 SPIRIT

    November 30 December 01, 2017 | Maritim proArte Hotel Berlin, Germany

    The Pharma TechOps Sessions

    The 2.5-day event is a unique combination of

    Inspirational keynotes Panel discussions

    Well moderated, interactive World Caf sessions

    Challenge Your Peers roundtables

    Be part of our exclusive platform to explore various business models, case studies actions to increase profitability and identify missing gaps that hide opportunities business chances for your challenges.

    The 2.5-day event is a unique combination of

    Inspirational keynotes Panel discussions

    Well moderated, interactive World Caf sessions

    Challenge Your Peers roundtables

    Be part of our exclusive platform to explore various business models, case studies actions to increase profitability and identify missing gaps that hide opportunities business chances for your challenges.

    Hundreds of maintenance & engineering projects and technology budgets under the same roof

    Get involved at the event as a Business Partner. For our event partners it is a one-stop-shop opportunity to promote thought-leadership and get face-to-face with over 100 key prospects.

    Pharma TechOps offers the best in class opportunity to introduce yourself as a thought leader to pharma professionals involved in maintenance and plant availability projects.

    Get involved at the event as a Business Partner. For our event partners it is a one-stop-shop opportunity to promote thought-leadership and get face-to-face with over 100 key prospects.

    Pharma TechOps offers the best in class opportunity to introduce yourself as a thought leader to pharma professionals involved in maintenance and plant availability projects.

    Highlight Speakers 2017

    Biggest pharma companies

    Biggest pharma companies

    Head of Global Manufacturing

    The Grünenthal Group

    Biggest pharma companies

    Biggest pharma companies

    Dr. Dieter Peters, Head of Global Manufacturing, The Grünenthal Group

    Dieter Peters, born 1956, received his PHD at the University of Dortmund in chemistry. From 1986 to 1996 he worked at Hoechst AG and from 1996 to 2002 at Celanese AG. In 2002 he joined the Gr nenthal Group Switzerland as Managing Director. From October 2011 to May 2017 he worked as Head of Global Product Supply and since May 2017 he is the Head of Global Manufacturing. He is an expert in turn arounds and restructuring.

    Challenge Your Peers

    Operational Excellence in Pharma Manufacturing Technology, Capacity and Availability management in manufacturing can provide significant advantages to business – HOW?

    • How can pharma catch up with state of the art management processes, employee involvement and continuous improvement culture that are daily routine in other industries? (Deliverables: Key must haves to accomplish that)
    • What are you doing in your company to catch up and which benefits have you realized? (Deliverables: Changes you have implemented and your measurable business advantages)
    • What are you doing to discover the true waste in your processes and become more productive and service oriented? (Deliverables: What barriers did you overcome, what did you find which wasn t so obvious, what are your most memorable wins)
    • How do you work with regulatory requirements and departments to realize innovation and mitigate risk? (Deliverables: Examples of change and cooperation with regulatory colleagues to make it happen)
    • Who is driving innovation and change in your company what is your role? (Deliverable: Examples to make an Innovation out of an invention)
    • How do you efficiently connect R D and Manufacturing? (Deliverables: Example processes and Best Practice process)
    • How do you integrate external manufacturing in established and innovative products manufacturing? (Deliverables: Role model examples and lessons learned from challenged cooperation)

    The Gr nenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation.

    Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a 2 billion company.

    We are a fully integrated research development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R D above the industrial average, we are strongly committed to innovation.

    Gr nenthal is an independent, family-owned company headquartered in Aachen, Germany. We are present in 32 countries with affiliates in Europe, Latin America and the US. Our products are sold in more than 155 countries and approx. 5,500 employees are working for the Gr nenthal Group worldwide. In 2016, Gr nenthal achieved revenues of approx. 1.4 bn.





    Biotech Industry, Biotech News, Biotechnology Articles, fda and pharmaceutical industry.#Fda #and #pharmaceutical #industry

    fda and pharmaceutical industry

    Certain microRNAs in the saliva of concussion patients could help gauge the severity of concussions and predict the length of concussion symptoms.

    Fda and pharmaceutical industry

    Toxicity knocks Ardelyx s hyperkalemia hopes back to preclinic

    Unexpected side effects have spelled the end for Ardelyx’s drug candidate to treat elevated potassium levels in the blood, which was in phase 3 testing.

    Fda and pharmaceutical industry

    Cytokinetics cans lead drug after phase 3 ALS wipeout

    Cytokinetics canned tirasemtiv after it failed to beat placebo against the primary endpoint or any of the secondary goals in an ALS trial.

    Fda and pharmaceutical industry

    Step Pharma bags cash for CTPS1 autoimmune R D drive

    The $17 million financing equips the lean French biotech to prepare its CTPS1 inhibitors for clinical testing in autoimmune disorders.

    Fda and pharmaceutical industry

    PTK6 blocker could treat or even prevent ER+ breast cancer metastasis

    The enzyme PTK6 could be targeted to quell the growth of estrogen receptor-positive breast cancer, a common form of the disease.

    Fda and pharmaceutical industry

    Amsterdam beats out Milan to host EMA

    After tying with Milan in a third round of voting, Amsterdam will be the new home of the European Medicines Agency.

    Fda and pharmaceutical industry

    LivaNova to offload Cardiac Rhythm unit for $190M

    LivaNova will sell its Cardiac Rhythm Management business to its joint venture partner, MicroPort Scientific.

    Fda and pharmaceutical industry

    DBV climbs as peanut allergy safety data come in clean

    Shares in DBV rose on the back of the data, going a little way to erasing the big drop it suffered after missing its primary efficacy endpoint.

    Fda and pharmaceutical industry





    Healthcare business news, research, data and events from Modern Healthcare, health industry news.#Health #industry #news

    Modern Healthcare

    The leader in healthcare business news, research data

    Health industry news

    Sign-ups reach 2.3 million in first three weeks of ACA open enrollment

    Plan selections through HealthCare.gov during the first three weeks of the fifth ACA open enrollment continue to top last year’s sign-ups, though it’s unclear if the pace will continue until enrollment ends Dec. 15.

    CMS proposes overhaul of cardiac device coverage

    Health industry news

    The CMS has suggested major revisions to its implantable cardiac devices coverage policy to give patients faster access to the treatments. The reimbursement policies haven’t been updated since 2005.

    Net neutrality repeal threatens telemedicine

    Health industry news

    With net neutrality on the verge of repeal, some healthcare experts worry the industry, and especially rural organizations, will struggle with the policy changes.

    Research

    MASTERING MACRA: What you need to know about Medicare’s physician Quality Payment Program

    Health industry news

    MACRA’s approach to reimbursing physicians is here, but many doctors and administrators are still trying to get a handle on how it works. Read on for tips on how to deal with this major change to the Medicare payment system.

    Data Points: Is it time to talk?

    Health industry news

    Providers

    13 hospitals join CMS’ rural pay experiment

    Health industry news

    The CMS has expanded an experiment that pays rural hospitals the actual cost of care versus standard Medicare rates. Executives say the funds are key to ensure quality care.

    Insurance

    Uninsured rates lower in states that run their own ACA exchanges

    Health industry news

    Fewer people are uninsured in states that set up their own Affordable Care Act insurance exchanges than in states that use HealthCare.gov, data from the CDC shows.

    Government

    CMS expands value-based Medicare Advantage project to 25 states

    Health industry news

    Starting in 2019, insurers in 15 more states will be able to participate in Medicare Advantage’s value-based insurance design program. Plans encourage the use of high-value clinical services among chronically ill patients by lowering or eliminating cost-sharing.

    Finance

    Mayo Clinic doubles operating income in third quarter, giving ammo to critics of rural hospital cuts

    Health industry news

    While Mayo Clinic’s financials improved, it has endured harsh criticism from residents and public officials of Albert Lea, Minn., who decry Mayo’s decision to strip services from the rural community’s hospital.

    Technology

    Telemedicine is still hindered by limited reimbursement

    Health industry news

    On Black Friday, telemedicine visits soar. And they’ve been increasing year-round. But they’ve yet to truly take off, as they’re held back by old reimbursement models.

    Transformation

    Biomedical startup aims to change post-op care

    Health industry news

    Megan Frost founded a company that has created nitric-oxide-infused bandages and wound dressings to greatly reduce the risk of infection, especially in patients post-surgery.

    Safety & Quality

    New CMS quality measure tool in the works

    Health industry news

    The CMS is working on a new online resource that will make it easier for providers to figure out which quality measures are under development.

    People

    While axing the ACA mandate, why not replace it with a different coverage incentive?

    Health industry news

    Establishing an alternative continuous coverage mechanism could soften the coverage losses from repealing the ACA’s individual mandate as part of the GOP tax cut bill. But so far politics has gotten in the way of considering that.

    Surveys

    This week’s poll: Has Trump been good or bad for healthcare?

    Health industry news

    Share your opinion in the latest edition of our biweekly reader poll. Has Trump been good or bad for healthcare?





    INTERNATIONAL JOURNAL OF PHARMA SCIENCES AND RESEARCH (IJPSR), research pharma.#Research #pharma

    INTERNATIONAL JOURNAL OF PHARMA SCIENCES AND RESEARCH

    Research pharma

    Research pharma

    About IJPSR

    International Journal of Pharma Sciences and Research (IJPSR) is a non-profit making scientific electronic journal, publishing research and review articles, together with case studies, in the fields of Pharmaceutical Sciences and research. International Journal of Pharma Sciences and Research (IJPSR) is published monthly. International Journal of Pharma Sciences and Research (IJPSR) also publishes editorials, a letter to the editor section, surveys, and can function as an open discussion forum on significant issues of current interest. The journal content could be presented not only in print (pdf format) since it is published in an electronic format. Authors, therefore, are encouraged to submit their article or communication in the most appropriate medium to best convey their findings to members of International Journal of Pharma Sciences and Research (IJPSR).

    International Journal of Pharma Sciences and Research (IJPSR) is a scholarly open access, peer reviewed international journal with a primary objective to provide the academic community and industry for the submission of half of original research and applications related to Pharmaceutical Sciences. International Journal of Pharma Sciences and Research (IJPSR) mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences.

    Why One Should Publish With IJPSR:

    • Hassle Free Submission
    • Easy Tracking of Your Submitted Manuscript
    • Go-Getter Publication
    • Fast Processing Reviewing
    • Transparent Review Reporton Request
    • Easy access to the Content and Index

    Frequency: 12 issues per year

    Subject Category: Pharmaceutical Science

    Journal Title : International Journal of Pharma Sciences and Research (IJPSR)





    EY – Vital Signs – EY M – A Outlook and Firepower Report 2017 –

    EY M A agenda.

    The growth gap is the difference in the sales growth of a biopharma company or biopharma sub-sector relative to overall drug market sales. It is based on IMS Health s global drug market forecast and analysts estimates of company sales.

    The EY Firepower Index measures a company s ability to do M A based on the strength of its balance sheet. Together, a company s market capitalization, cash equivalents and debt capacity provide the firepower for deals. Thus, a company s firepower increases when either its market capitalization or its cash and equivalents rise or its debt falls. Access more details about the methodology and the assumptions underpinning the EY Firepower Index.

    More than any other time in the past several years, big pharma companies have the firepower advantage necessary to execute on the acquisitions they require to bolster revenue and drug pipelines. And more than any other time in the past several years, those deals are necessary.

    Big pharma and biotech s race for inorganic growth has intensified as payers continue to push back on price increases for older drugs and dampen the growth trajectory of newer therapies. M A has averaged above US$200 billion over the past three years impressive heights which we deemed the new normal in last year s report. Even so, 2017 could be a banner year for dealmaking, well exceeding this level as industry and political forces converge.

    Vital pharma

    Pricing pressure

    Although 2016 marks the first time in several years that big pharma s growth gap has not materially expanded, a significant gap remains. In fact, while big pharma has returned to growth in 2016, its growth rate is just shy of the overall market.

    Evidence of payers impact was easy to find in 2016. As companies struggle to boost market share in diabetes, for example a market already accustomed to contracting with payers pricing has eroded more quickly than expected across multiple diabetes drug classes.

    Biosimilars, now established in emerging market countries, are poised to capture share and are pressuring margins in developed markets as well. And market forecasters may only now be beginning to discount biosimilars potential impact on payer pressure, which may eventually accelerate market erosion in classes with several competitors vying for share.

    Finding the drug price white space can hedge against payers ability to limit growth, but may require pharma to pursue higher-risk, global market opportunities. This quest may also drive future M A as companies compete for the best assets in key therapeutic areas where drug sales currently represent a smaller portion of total related health care costs.

    Who s buying (and selling) what?

    Vital pharma

    Heading into 2017, we expect dealmakers to return to the table in earnest. From 2014-16, yearly M A totals averaged around US$200 billion, but as a group, big pharma has spent on average only 10% of its firepower each year. The strategic drivers and deal conditions are set. In a global poll by EY in mid-October, we saw early signs of this uptick: 43% of life sciences executives claimed to have five or more deals in the works, as opposed to just 6% in our mid-April poll.

    Biotech and big pharma valuations fell steadily throughout the year before the post-election bounce as drug pricing concerns gained momentum. The last time biopharma valuations experienced such acute declines was during the 2008 financial crisis. This pronounced downturn was quickly followed by a handful of 2009 megadeals, so there s a precedent for big pharma ramping up dealmaking in 2017 and potentially dominating M A share for several years.

    Falling firepower

    Vital pharma

    Falling equity valuations and debt raised to fuel previous years M A have resulted in a roughly 20% industry-wide firepower decline. Specialty pharma firepower and big biotech firepower account for about half the decline.

    Big pharma now nearly equals its largest share of industry firepower in four years. Despite the overall decline, capital allocation priorities favor continued M A among industry s largest players.

    Most big pharma and some big biotechs have forecast growth through 2020 below the IMS-projected 4% global revenue growth rate for the sector. Pricing pressure on new therapies has impeded recovery from the industry-wide patent cliff that began several years ago. Companies with growth gaps and shrinking firepower are in the most challenging positions.

    Firepower unleashed record M A in 2017?

    The marketplace reaction to biopharma companies third quarter earnings calls suggests investors did not fully appreciate the industry s pricing problems. As the probability of revenue shortfalls increases across the industry, even companies with ostensibly solid growth prospects may pursue M A to guard against downside scenarios.

    There had been pent-up demand for deals in a holding pattern going into the US presidential election, but the deal chatter in the waning weeks of 2016 indicate much firepower could soon be unleashed in 2017 based on these drivers:

    • The payer growth gap has become a reality
    • Finding growth in traditional strongholds is becoming increasingly difficult
    • Plenty of firepower remains unspent
    • US political climate becomes more favorable
    • Waning ex-US advantages

    Certain companies may alternatively or in parallel pursue further diversification away from the pharma core business. Non-core businesses may be the road less traveled for most of pharma, but they are projected to account for around US$150 billion in sales in 2016 out of a total of US$500 billion. We expect transactions in most, if not all, subsectors in 2017.

    Divestitures, therapeutic battlefield consolidation and activity in remaining unmet therapeutic needs might easily yield another year of US$200 billion in deal volume, even without such favorable M A conditions. But unprecedented payer pressure, a deal tailwind from macro forces, and an unusually full M A pipeline, is likely to push biopharma dealmaking to new heights in 2017.

    See also other related EY articles and papers:





    Generic Drugs – Pharmacy News – Drug Store News, generic drug company.#Generic #drug #company

    Generic Drugs & Pharmacy News

    Generic drug company

    FDA approves Glenmark’s generic Hailey Fe 1/20

    The contraceptive had U.S. brand and generic sales of roughly $116.8 million, according to data from IQVIA for the 12 months ended September 2017.

    Generic drug company

    Ajanta launches generic Kapvay

    Generic drug company

    FDA approves Cipla’s generic Pulmicort Respules

    Generic drug company

    Q s bread and butter and the years to come hold a lot of promise.

    Generic drug company

    Biosimilars poised to bring savings — if they get to launch

    Even as more approvals roll in and industry officials talk about how biosimilars will bring significant savings in the coming decade, there is a concern that regulatory and reimbursement hurdles could prevent the industry from realizing the full savings of the less-expensive alternative to biologics.

    Generic drug company

    Amid challenges, generics industry gets FDA assist to ID new areas of need

    As the generics industry squares off against price deflation, manufacturers are looking for new product areas in need of lower-cost alternatives and recent Food and Drug Administration efforts are helping with the discovery process.





    Drug Channels: Why Walmart Is Finally Joining McKesson for Generic Purchasing, generic drug company.#Generic #drug

    generic drug company

    Generic drug company

    Here are four key points to understand about yesterday s Walmart-McKesson announcement.

    • As part of Amerisourcebergen s supply agreement with Walgreens Boots Alliance (WBA), ABC can source generic drugs and other products through Walgreens Boots Alliance Development (WBAD). Note that ABC can cancel WBA s equity warrants if WBAD terminates the Generic Pharmaceuticals Purchasing Services Agreement. For background, see Why Walgreens Boots Alliance is Triggering a Huge AmerisourceBergen Stock Buyback.
    • Red Oak Sourcing is the generic purchasing joint venture between CVS Health and Cardinal Health.

    Unlike its wholesale peers, McKesson has channeled its customers generic purchasing volume into the company s own OneStop generic program, giving additional leverage and scale to McKesson s negotiations with generic manufacturers. In 2015, McKesson established McKesson Global Procurement Sourcing Limited, a London-based subsidiary focused on global manufacturer negotiations.

    Generic drug company

    The press release does not mention OneStop. Instead, it states that the companies will collaborate on sourcing generic pharmaceuticals for their respective U.S. operations, adding scale and value for both companies. Translation: Walmart is not ceding all authority to McKesson.

    • In 2014, Rite Aid shifted its purchasing to OneStop. This volume, however, will move to WBAD once WBA completes its Rite Aid acquisition. See point 6 in The Walgreens-Rite Aid Deal: Ten Things You Should Know.
    • Omnicare expanded its relationship with McKesson to include the supply of both brand-name and generic pharmaceuticals. (The companies previous agreement included only brand-name drugs.) Alas, CVS Health acquired Omnicare, which now sources generics via Red Oak.
    • McKesson had supplied brand-name drugs to the mail and specialty pharmacies of UnitedHealth s OptumRx PBM, which was McKesson s fifth-largest customer. Following OptumRx s acquisition of Catamaran, Cardinal Health signed an agreement with OptumRx to supply generic and brand pharmaceuticals to OptumRx’s pharmacies.

    McKesson s profits from the Walmart deal will not be as great as its profits from retailers that buy via OneStop. Since the companies will collaborate on generic sourcing, I presume that Walmart will share in more of the economics than would a typical customer.

    Generic drug company





    Company Meaning in the Cambridge English Dictionary, italian pharmaceutical companies.#Italian #pharmaceutical #companies

    Meaning of “company” in the English Dictionary

    company noun

    Thesaurus: synonyms and related words

    B2 [ U ] the fact of being with a person or people, or the person or people you are with:

    If you do something for company, you do it to make you feel as if you are not alone:

    B2 to stay with someone so that they are not alone:

    Thesaurus: synonyms and related words

    You can also find related words, phrases, and synonyms in the topics:

    company noun ( THEATRICAL GROUP )

    Thesaurus: synonyms and related words

    company noun ( GROUP )

    Thesaurus: synonyms and related words

    You can also find related words, phrases, and synonyms in the topics:

    Idiom(s)

    “company” in American English

    company noun

    company noun ( BUSINESS )

    company noun ( OTHER PEOPLE )

    › [ U ] the state of having someone with you, or the person or people who are with you:

    company noun ( GROUP )

    › [ C ] A company is also a military unit consisting of a large group of soldiers, usually with a captain in charge of them.

    “company” in Business English

    company noun [ C ]

    See also

    Help us add to the Cambridge Dictionary!

    These examples are from external sources. Click on the icon to tell us what you think.

    company

    Blogs about “company”

    syarikat, tamu, teman

    empresa, compañía, invitados

    компания, общество, гости

    azienda, società, compagnia

    şirket, kuruluş, ortaklık

    przedsiębiorstwo, firma, towarzystwo

    compañía, visita, empresa

    công ty, khách khứa, tình bạn hữu

    กลุ่มคนที่มีจุดประสงค์มาร่วมกันเพื่อธุรกิจ, แขกผู้มาเยี่ยม, ความเป็นเพื่อน

    empresa, companyia, visita

    perusahaan, tamu, teman

    Get a quick, free translation!

    • companion
    • companionable
    • companionship
    • companionway
    • company
    • company accounts
    • company car
    • company director
    • company doctor

    Create and share your own word lists and quizzes for free!

    More meanings of “company”

    Word of the Day

    an energetic happy person who enjoys being with other people

    Italian pharmaceutical companies

    Italian pharmaceutical companies

    • It s free!
    • Build your own word lists
    • Create quizzes
    • Save favourites
    • Share with friends
    • Personalise your My Dictionary space

    Add Cambridge Dictionary to your browser in a click!

    Add the power of Cambridge Dictionary to your website using our free search box widgets.

    Browse our dictionary apps today and ensure you are never again lost for words.





    Home, GSK, global healthcare companies.#Global #healthcare #companies

    About us

    We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

    About us

    What we do

    Our purpose and strategy

    Governance

    Comic Relief partnership

    Save the Children partnership

    We research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.

    Products

    We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare

    Products

    Our consumer healthcare business has a portfolio of some of the world’s most trusted and best selling products in Pain Relief, Oral health, Respiratory, Nutrition and Skin health

    Careers

    We are a global company delivering billions of healthcare products a year. Choose your path.

    Careers

    Apprentices, students and graduates

    Postgraduate opportunities

    We are a global company delivering billions of healthcare products a year. Choose your path.

    Investors

    Information and tools for investors including share and dividend information, share price analysis, latest news and corporate reporting

    Investors

    Shareholder information

    Corporate reporting

    Share price analysis

    Stock exchange announcements

    Discover our latest financial performance announcement and search for historical quarterly results materials

    Media

    Explore the latest news, different ways to stay in touch and available useful resources

    Media

    Resource centre

    Social media

    Keep up to date with our news and recent announcements

    Research

    Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines

    Research

    What we are working on

    How we discover our new products

    R D locations

    Open innovation

    Trials in people

    Sharing our research

    Research funding

    Our use of animals

    Learn more about our R D legacy involving the development of a broad range of innovative medicines, vaccines and consumer healthcare products

    Responsibility

    Responsible business is how we do business. Our special purpose is to help people do more, feel better, live longer

    Responsibility

    Health for all

    Our behaviour

    Our people

    Our planet

    Responsibility reports data

    Our part in tackling global health challenges and our aim to extend the benefits of our products to more people

    Global healthcare companies

    Behind the science We won’t stop until we beat HIV

    Global healthcare companies

    30 years and counting: the fight against HIV

    Juluca (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill – a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection

    Global healthcare companies

    Elaine’s story: following the journey of a respiratory medicine

    Global healthcare companies

    3D remodelled DNA helix structure

    About us We want to help people do more, feel better, live longer.

    Today there are still millions of people without access to basic healthcare, thousands of diseases without adequate treatments and millions more people who suffer from everyday ailments. At GSK we want to change this.

    Press releases

    London

    Share price at

    LSE price updated every 15 minutes. Timezone BST

    Share price at

    NYSE price updated every 20 minutes. Timezone EST

    Tweets from GSK

    1. Global healthcare companies

    GSK GSK

    #DYK your immune system ages just like you do? Give it a helping hand, talk to your doctor about adult vaccinations… twitter.com/i/web/status/9…

    about 17 hours ago

  • Global healthcare companies

    GSK GSK

    Meet Elaine – she’s a champion of medicines for patients across the globe. Read her story: gsk.to/2iHSrOS… twitter.com/i/web/status/9…

    about 19 hours ago

  • Global healthcare companies

    GSK GSK

    Vaccination isn’t something you outgrow #VaccinateForLife Global healthcare companies

    Find out more

    Global healthcare companies

    Our products

    We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare

    Global healthcare companies

    Career opportunities at GSK

    Discover the work we do and the opportunities that exist, from research and development through to making our products available to those who need them

    Global healthcare companies

    Health for all

    Our medicines, vaccines and consumer healthcare products are improving quality of life for patients and consumers around the world.

    © 2001-2017 GlaxoSmithKline plc. All rights reserved.

    GlaxoSmithKline plc. Registered in England and Wales No. 3888792.

    Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.





  • Biotechnology, Advanced Academic Programs, Johns Hopkins University, biotechnology industry news.#Biotechnology #industry #news

    Biotechnology

    Quick Stats

    The Johns Hopkins MS in Biotechnology offers a comprehensive exploration of basic science, applied science, and lab science, with an industry focus. The program gives you a solid grounding in biochemistry, molecular biology, cell biology, genomics, and proteomics.

    This 10-course degree program is thesis-optional, part-time, and can be completed fully online. Our curriculum will prepare you to engage in research, lead lab teams, make development and planning decisions, create and apply research modalities to large projects, and take the reins of management and marketing decisions.

    Many students like the flexibility of the general degree; it allows them to tailor the coursework to meet their individual career goals. The program also offers five different concentrations: biodefense, bioinformatics, biotechnology enterprise, regulatory affairs, or drug discovery.

    Onsite courses are taught during evenings or weekends at either the university s Homewood Campus in Baltimore, MD or the Montgomery County Campus in Rockville, MD. Courses are also offered in our state-of-the-art lab.

    National Cancer Institute Fellowship

    Each year, students of the MS in Biotechnology have the opportunity to apply for a fellowship with the National Cancer Institute at NIH. This fellowship, which requires onsite research as well as onsite courses for the Molecular Targets and Drug Discovery Technologies concentration at the Montgomery Count Campus, awards students with a stipend while providing them with useful experience in the arena of cancer research. Learn more about this fellowship and apply here.

    State-specific Information for Online Programs

    *Note: Students should be aware of state-specific information for online programs. For more information, please contact an admissions representative.





    Global Healthcare: Seeing Clearly: Ultrasound Future of Diagnostic Imaging, global healthcare companies.#Global #healthcare #companies

    global healthcare companies

    Global healthcare companies

    Handheld Ultrasound: A Quintessential Disruptive Technology

    Global healthcare companies

    Disrupting the U.S. Medical Imaging Market

    Global healthcare companies

    Reenita Das, a partner with Frost Sullivan, adds color to this in her recent Forbes article Could Plug-and-Play Be the Future of Healthcare Diagnostics?. She points out that software enhancement tools are improving ultrasound image quality to such a degree that the technology can now be used to identify and monitor cancer and other diseases. She points out that avoiding the need for painful biopsy and dangerous radiocontrast agents where possible will “significantly reduce the pain and cost of treatment for cancer patients.” In view of this, ultrasound’s potential to begin replacing other imaging modalities appears much larger. Its ability to do that while simultaneously lowering costs is what makes it so valuable.

    Questions For Discussion

    • Has the image quality of handheld ultrasound devices achieved parity with the larger, more expensive machines?
    • Can companies like Mobisante effectively target the core medical imaging market in the U.S.?
    • Could handheld ultrasound devices really save the U.S. over $50 billion per year?

    13 comments:

    Global healthcare companies

    Valuable Addition– A friend who was an executive at GE Healthcare made this comment to me by email: The medical profession [plays] a role in adoption of disruptive technologies (not just the GE s and Philip s). Radiologists have been especially successful at introducing quality criteria and credentialing requirements to block other specialities from being reimbursed for imaging. And, physicians are still in a pay me to use it mindset when it comes to technology – reimbursement is a prerequisite for technology adoption.

    Global healthcare companies

    In fact, the two best-known examples of handheld ultrasound in the world were created in India.

    Global healthcare companies

    A sometime employee of GE that worked on the Vscan Access device let me know that the Vscan was technically created within the Vingmed GE ultrasound group in Norway: http://www.heart-sfi.no/index.php?page=ge-vingmed-ultrasound-gevu . However, the media surrounding the product release still suggest that the inspiration was India.

    Global healthcare companies

    Compared with many other diagnostic devices, ultrasound seems to be safe with no side effects. It doesn t expose patients to harmful radiation like CT scans and X-rays does. Furthermore, it is comparatively inexpensive than other diagnostics and easily available in every healthcare facilities, thus it has become crucial in medicine. It is helpful in viewing the heart, kidneys, liver, blood vessels, and other organs of body.

    Global healthcare companies





    Pharmaceutical industry news, articles, jobs, reports, advice and services, pharma advertising agencies.#Pharma #advertising #agencies

    First Herceptin biosimilar cleared in Europe

    Pharma advertising agencies

    Ontruzant is approved for all the same indications as Roche s blockbuster

    EMA forges closer ties with HTA umbrella group

    Pharma advertising agenciesAgrees joint work plan with the European Network for Health Technology Assessment

    Novartis’ orphan drug Tasigna wins EU expanded indication

    Pharma advertising agenciesThe CML medication can now treat paediatric patients

    Amsterdam picked to host the European Medicines Agency

    Pharma advertising agenciesBut regulator faces a challenging relocation project to depart from London

    Concordia accused of overcharging NHS for thyroid drug

    Pharma advertising agenciesThe pharma firm said to have abused its position within the UK market

    Sales news

    Research news

    Pharma advertising agencies

    The state of trust

    Roche s Future-proofing Healthcare event shows how the current model is a complicated one

    Marketing news

    Regulatory news

    Pharma advertising agencies

    Revolutionising how healthcare is delivered

    The big technology shift sweeping the global connection of healthcare

    Appointments

    Press releases

    PMHub Videos

    Healthcare news

    The Gallery

    A visual showcase of agency work. Track down an agency from the image, track down your competitors’ work, search by product or therapy area to pull up, for example, cardiovascular campaigns. Click here for a portfolio of hundreds of campaign visuals – updated regularly – free for you to reference. Agencies – to add your work to The Gallery please contact us.

    Pharma advertising agencies

    Pharma advertising agencies

    Pharma advertising agencies

    Pharma advertising agencies

    Pharma advertising agencies

    MHRA joins Instagram as part of Yellow Card drive

    UK medicines regulator follows in the footsteps of NICE in using the channel

    Pharma advertising agencies

    Annalisa Jenkins joins biomarker firm PlaqueTec as CEO

    She arrives from US-based Dimension Therapeutics, where she was CEO

    Pharma advertising agencies

    Is AI changing the future of healthcare?

    How technology is playing a big role in healthcare

    Pharma advertising agencies

    Proving the Strategic Value of Patients

    Pharma advertising agencies

    Tony de Fougerolles joins Evox Therapeutics as CEO

    He succeeds Dr Per Lundin who stays at the firm as COO

    Pharma advertising agencies

    Teva launches personalised digital support for MS patients

    Says its MS Care Programme is the first of its kind

    Pharma advertising agencies

    What value for innovation in an era dominated by affordability?

    Pharma can collaborate but must be clear about its motives

    Pharma advertising agencies

    The Future of Marketing in Life Sciences: Is your function fit for purpose

    Pharma advertising agencies

    Do you want to see a magic trick?

    Key points that drive behaviour change

    Pharma advertising agencies





    Pharmaceutical Market and Healthcare Services in Poland and Eastern Europe, pharmaceutical market analysis.#Pharmaceutical #market #analysis

    tekst z obrazka

    Pharmaceutical market analysis

    The Health Ministry on 19 August published for consultation a draft update of the reimbursement lists, due to take effect on 1 September. Under the proposal, 23 new products (EAN codes) are to be added to the pharmacy . more

    Pharmaceutical market analysis

    Dr. Max, which was is owned by Penta Investments, was the largest independent pharmacy chain in Poland (not owned by a wholesaler) even before the acquisition of Mediq, and the acquisition of the latter would make it . more

    Roche (along with Genentech, a Roche subsidiary) has protection from competition for Mabthera and Rituxan (rituximab a monoclonal antibody which targets CD20, used to treat B cell malignancies and B cell-mediated . more

    Pharmaceutical market analysis

    Pharmaceutical market analysis

    Pharma market set to rebound in 2013

    Oncological pharmaceuticals and immunosuppressive drugs were the driving force pushing the growth of the pharmaceutical market in 2008-2009. The . more

    Pharmaceutical market analysis

    Rynek farmaceutyczny w Polsce odbije siк w 2013 r.

    W latach 2008-2009 r. leki onkologiczne i immunomoduluj±ce byіy motorem wzrostu rynku lekуw. Gіуwn± tego przyczyn± byіa zmiana statusu . more

    Pharmaceutical market analysis

    Reimbursement Act had a strong impact on the pharmaceutical distribution segment in Poland

    The years 2013-2014 will be affected by the implications of the Reimbursement Act too, though the impact will be less severe than . more

    Pharmaceutical market analysis

    PMR is a market research and consulting company active within over 25 countries of Central and Eastern Europe. Since 1995 we have been working for more than 500 global corporations, as well as for many regional companies.

    Each year we run around 200 custom projects for our clients assisting them to continuously increase their market share, successfully enter new territories and optimise costs.

    PMR consultants, analysts and researchers create premium value for companies that need:





    Biotech Industry, Biotech News, Biotechnology Articles, pharma advertising agencies.#Pharma #advertising #agencies

    pharma advertising agencies

    Certain microRNAs in the saliva of concussion patients could help gauge the severity of concussions and predict the length of concussion symptoms.

    Pharma advertising agencies

    Toxicity knocks Ardelyx s hyperkalemia hopes back to preclinic

    Unexpected side effects have spelled the end for Ardelyx’s drug candidate to treat elevated potassium levels in the blood, which was in phase 3 testing.

    Pharma advertising agencies

    Cytokinetics cans lead drug after phase 3 ALS wipeout

    Cytokinetics canned tirasemtiv after it failed to beat placebo against the primary endpoint or any of the secondary goals in an ALS trial.

    Pharma advertising agencies

    Step Pharma bags cash for CTPS1 autoimmune R D drive

    The $17 million financing equips the lean French biotech to prepare its CTPS1 inhibitors for clinical testing in autoimmune disorders.

    Pharma advertising agencies

    PTK6 blocker could treat or even prevent ER+ breast cancer metastasis

    The enzyme PTK6 could be targeted to quell the growth of estrogen receptor-positive breast cancer, a common form of the disease.

    Pharma advertising agencies

    Amsterdam beats out Milan to host EMA

    After tying with Milan in a third round of voting, Amsterdam will be the new home of the European Medicines Agency.

    Pharma advertising agencies

    LivaNova to offload Cardiac Rhythm unit for $190M

    LivaNova will sell its Cardiac Rhythm Management business to its joint venture partner, MicroPort Scientific.

    Pharma advertising agencies

    DBV climbs as peanut allergy safety data come in clean

    Shares in DBV rose on the back of the data, going a little way to erasing the big drop it suffered after missing its primary efficacy endpoint.

    Pharma advertising agencies





    Pharma Machines, Home, pharma equipment.#Pharma #equipment

    Pharma Machines Ltd UK, Suppliers of Used Pharmaceutical Processing Machines and Pharmaceutical Packaging Machinery

    These are our latest arrivals – to view our entire stock click on Machines

    Well maintained used pharmaceutical machines and pharmaceutical packaging machinery are often a viable alternative to new equipment with high costs and long delivery times.

    Pharma Machines Ltd have been suppliers of used Pharmaceutical Machines and Pharmaceutical Packaging Machinery since 1975.

    We supply a wide range of Pharmaceutical machines from process and manufacturing to packaging machinery. These range from laboratory size to production scale.

    We are proud to have been suppliers of pharmaceutical machines to the Pharmaceutical Industry world-wide from our premises in and around London, UK for more than 40 years.

    In our works in East Grinstead near London Gatwick Airport, UK we exhibit used pharmaceutical machines for processing and manufacturing and also pharmaceutical packaging machinery.

    The majority of these machines can be seen running and we can often demonstrate machines with customer’s placebo product or packaging materials.

    We regularly supply machinery manufactured by major European and World manufacturers

    Aeromatic, Alexanderwerk, Allen, All-Fill, Al-Tech, Alpine, Apex, Bausch Ströbel, Becomix, Bepex-Hutt, BFB, Bohle, Bosch, Bosspak, Brevetti, Brogli/Brog-tec, Brucks,

    CAM, Caleva, Capsugel, Collette, Courtoy, Cozzoli, Cremer, Diosna, Distek, Driam, Ehret, Eisai, Erweka, Etipack, Farmomac, Fette, Fielder, Fitzpatrick, Frewitt, Fryma,

    Garvens, Gilowy, Giusti, Glatt, Groninger, Haagen Rinau, Harland, Heraeus, Herma, IMA, IWKA, Inova, Kalix, Kecol, Kilian, King, Klöckner, Korsch, Koruma, Kraemer, Krieger,

    Lancer, Lock, Loma, Macofar, Manesty, Marchesini, Maschimpex, Mettler Toledo, MG 2, Memmert, Miele, Multipack, Munters, Neri, Newman, Noack, Norden, Omas, Ottenschläger,

    Pammasol, Pam, Pester, Pharma Test, Prisma, Pharmatron, Quadro Engineering, Romaco, Rota, Rovema, Russell, Safeline, Seidenader, Seitz, Siebler, Silverson, Skerman, Swiftpack,

    Tonazzi, Uhlmann, Universal, Vankel, Vestec Morritz, Volpack, Vrieco, Watson Marlow, WA Bachofen, Willet, Winkworth, Zanasi, Zanchetta.

    Suppliers of Used Pharmaceutical Machines and Pharmaceutical Packaging Machinery





    Healthcare Advertising, HCB Health, pharma advertising agencies.#Pharma #advertising #agencies

    We go where other agencies don’t

    Our development team knows how to evaluate a mobile health experience and expedite a regulatory review.

    Our account team knows how to implement a project plan and implant a spinal device.

    News Feed | What healthcare challenge keeps you up at night? Contact us Pharma advertising agencies

    Pharma advertising agencies

    A viral, award-winning campaign that increased pageviews by 28%

    Pharma advertising agencies

    Pharma advertising agencies

    A disruptive print and collateral campaign that unified a brand and empowered customers

    Pharma advertising agencies

    A campaign that shifted the spotlight to a pharma company’s outsourcing services

    Pharma advertising agencies

    An integrated campaign for a product launch that exceeded client expectations

    Pharma advertising agencies

    A launch strategy that helped doctors identify the right patients for an epilepsy drug

    Pharma advertising agencies

    A DTC campaign that gives patients the power to take control of their vision

    Pharma advertising agencies

    An award-winning ad campaign that both consumers and surgeons loved

    Pharma advertising agencies

    Pharma advertising agencies

    A poster campaign that lightened up the conversation about breast cancer

    Pharma advertising agencies

    A brand overhaul that changed the way doctors prescribed a diuretic drug

    Pharma advertising agencies

    An aggressive rebrand that maintained market share and headed off a newcomer

    Pharma advertising agencies

    A campaign and loyalty program that increased prescription vitamin adherence by 54%

    Pharma advertising agencies

    A website that engages and educates surgeons to help them master cataract surgery

    Pharma advertising agencies

    An osteoporosis campaign that addressed non-compliance and grew sales by 48%

    Pharma advertising agencies

    A mobile health and fitness app that is combating childhood obesity and chronic disease

    Pharma advertising agencies

    A TV campaign that communicates local care for cancer treatment

    Pharma advertising agencies

    A modern website that is easily scalable for employees and easily accessible for consumers

    Pharma advertising agencies

    An iPad app perfect for demonstrating equipment that isn’t portable

    Pharma advertising agencies

    A global campaign that brought the value of the LuxOR™ Ophthalmic Microscope to life

    Pharma advertising agencies

    Pharma advertising agencies

    A surgical iPad game that helps surgeons better understand patient selection

    Pharma advertising agencies

    The first iBook we produced for a client caught the attention of Apple





    Pharmaceutical Microbiology, recent pharmaceutical news.#Recent #pharmaceutical #news

    Pharmaceutical Microbiology

    Microbiology, pharmaceuticals, healthcare and contamination control news and discussion site. Edited by Dr. Tim Sandle (established 2010)

    Pages

    Recent pharmaceutical news

    Wednesday, 22 November 2017

    Justification of starting materials for the manufacture of chemical active substances

    Recent pharmaceutical news

    Tuesday, 21 November 2017

    Q Pharmig20 and you or your company will be invoiced accordingly.

    Microbial Control of Pharmaceutical Water Systems

    Recent pharmaceutical news

    Sunday, 19 November 2017

    Biocidal cleaners may spread multidrug resistance in MRSA

    Recent pharmaceutical news

    Saturday, 18 November 2017

    Examining the lifestyles of microbes

    Recent pharmaceutical news

    Friday, 17 November 2017

    Bacterial signalling in sharper resolution

    Recent pharmaceutical news

    Thursday, 16 November 2017

    ISO/IEC 17025 moves to final stage of revision

    Recent pharmaceutical news

    Wednesday, 15 November 2017

    Past, present, and future perspectives on the LAL reagent

    Q A covering past, present, and future perspectives on the LAL reagent

    Recent pharmaceutical news

    JD: Actually, we use all four methods: gel-clot, kinetic turbidimetric, kineticchromogenic and the PTS . These methods are used to test and release incoming raw materials and to evaluate intermediate formulation buffers that are subsequently used to produce licensed LAL products. Our accessory products also benefit from the use of these methods prior to release. Finally, we leverage all of these techniques in developing and validating LAL test methods for customer-specific products.

    How did the introduction of the LAL test change our industry?

    What are the key trends in endotoxin and LAL testing? What advances have been made?

    What new challenges will be faced in the years to come?





    Mainstream Normalizes Pedophilia with – Victoria Secret – Style Lingerie Show Featuring 5yo Girls, thompson

    Mainstream Normalizes Pedophilia with Victoria Secret -Style Lingerie Show Featuring 5yo Girls

    A highly disturbing Victoria’s Secret-style lingerie show featuring 5-year-olds highlights the push to normalize pedophilia in the mainstream.

    The latest movement within media and Hollywood pop culture is a distinctive agenda to normalize pedophilia and the sexualization of children. The latest example of this growing trend within mainstream media is a fashion show that many feel crossed the line from – with scantily clad girls, who appear to be as young as five-years-old, walking the runway in a Victoria’s Secret–style show.

    The show, held at a shopping mall in China, revealed shocking images of young girls wearing nothing but lingerie, costume wings, and headpieces. This comes on the heels of Kim Kardashian sparking controversy last month after she posted images of her new children’s line, which included a bikini and lace slip dress.

    “I’m not dressing my 4-yr-old daughter in a leopard n lace slip dress Kim Kardashian Kids Line,” one disgruntled parent replied.

    What you see talking place is simply the latest manifestation of what is, without question, a creeping agenda within the mainstream of pop culture to normalize and force public acceptance of pedophilia.

    In the current age of political correctness, some sects of society know no limits as to how far they will go to force acceptance to avoid offending others. In one extreme case of forcing such political correctness, Salon magazine implies that society must be accepting of pedophiles. In two separate articles, Salon refers to pedophilia as an ‘alternate sexual preference’ and suggests that society should embrace these differences by insinuating that this poor man is just misunderstood.

    The article and video on Salon deal with pedophiles known as ‘non-offending’ — meaning while these individuals admit they are sexually attracted to prepubescent children, they claim they’ve never acted on it. However, the subject of one Salon article, Todd Nickerson admitted to seeking out jobs as a babysitter and noted that he “fell in love” with a five-year-old whom he babysat.

    The U.S. corporate mainstream media is, without a doubt, the most sophisticated propaganda operation in the history of humankind, according to political philosopher Noam Chomsky, author of Manufacturing Consent: The Political Economy of Mass Media.

    The mainstream media works diligently to alter and shape our perceptions and values. It seems clear that the propagandists are attempting to engineer a society that is accepting of pedophilia as a normalized behavior.

    Both Elijah Wood and Corey Feldman have publicly discussed the fact that Hollywood is a den of pedophilia – noting that numerous powerful moguls and others within the Hollywood scene prey on the vulnerable like “vultures.”

    Revealing exactly how the normalization propaganda operates, the New York Times published an op-ed proclaiming that pedophilia is “not a crime” – instead sympathetically characterizing pedophilia as a “disorder” that “these people [pedophiles] are living with.”

    The sell is that people who rape, or who fantasize about exploiting or raping children are portrayed as victims living with a condition that they have little choice over. The article goes on to insert tidbits about “recent studies,” which is an appeal to authority meant to imply that the author’s normalization agenda is backed by science.

    Thus, claims such as: “Men with pedophilia are three times more likely to be left-handed or ambidextrous, a finding that strongly suggests a neurological cause,” leaving readers to discern the credibility of the author s opinion based on an unprofessional interpretation of the actual study.

    Essentially, the idea being forwarded is that people who want to have sexual relations with children are suffering from a “disorder,” and thus are not subject to a moral evaluation, but instead are in need of compassion. The idea that pedophilia is a “condition,” rather than an internal mental process involving desires and attitudes, leaves the pedophile blameless.

    It’s clearly a sign of the times when the New York Times devotes more time to making excuses for pedophilia than it does defending innocent and victimized children!

    Interestingly, the CEO of the New York Times, Mark Thompson, was involved in the cover-up of cases involving British child rapist Jimmy Saville who raped as many as 500 children over the coarse of his career – while being protected by media moguls and celebrities alike.

    Further revealing the nefarious agenda, when recent news broke of a massive pedophile ring being busted in Norway, numerous mainstream outlets deleted published reports on it – including the Washington Post, ABC News, and the New York Times.

    Actions such as these give pause as to what exactly is the agenda of these major media outlets engaging in such actions.





    FDA Compliance Management in der Pharma- und Biotechnologie-Industrie, pharma management.#Pharma #management

    pharma management

    Pharma management Pharma management Pharma management Pharma management Pharma management Pharma management Pharma management Pharma management Pharma management Pharma management Pharma management Pharma management Pharma management Pharma management Pharma management Pharma management Pharma management Pharma management Pharma management Pharma management

    Pharma management

    FDA-Compliance und ihre Bedeutung fьr Unternehmen

    Geht es um die Zulassung pharmazeutischer Produkte auf dem amerikanischen Markt, sind die strengen Bestimmungen der FDA (Food and Drug Administration) zu erfьllen. Alle Systeme, die an der Produktion pharmazeutischer Produkte fьr die USA beteiligt sind, mьssen daher validiert und FDA -compliant sein. In Europa wird die Zulassung fьr Arzneimittel oder gentechnisch hergestellte Prдparate von der European Medicinal Evaluation Agency (EMEA) erteilt oder entzogen. Die Entscheidungen der EMEA sind fьr alle Mitgliedsstaaten der Europдischen Union bindend.

    Betroffen davon sind dabei sowohl die Hersteller von Medikamenten und deren Zulieferer (Ausgangs- u. Hilfsstoffe, Gerдte u. Medizinprodukte, Hard- u. Software) als auch Unternehmen aus dem Bereich der klinischen und prдklinischen Forschung. Der von der FDA 1997 in Kraft gesetzte 21 CFR part 11, Electronic Records and Electronic Signatures, final rule regelt den Umgang mit elektronisch erzeugten und gespeicherten Daten sowie mit elektronisch geleisteten Unterschriften verbindlich. Zusдtzliche Qualitдtsregelwerke wie GMP (Good Manufacturing Practice), GLP (Good Laboratory Practice) oder GCP (Good Clinical Practice) legen neben den von den Behцrden FDA und EMEA formulierten Regelwerken allgemeine Validierungs-Richtlinien fest.

    Die Einhaltung ergдnzender Leitlinien und Qualitдtsnormen (ISO) stellen zwar keine behцrdlichen Anforderungen dar, sind jedoch die Grundlage fьr Qualitдtsverpflichtungen eines Anbieters gegenьber seinen Kunden. Das bedeutet konkret, dass die IT-Systeme und Prozesse der beteiligten Unternehmen ebenso wie die automatisierten Prozesse in Labor und Produktion FDA-compliant sein mьssen. Fьr elektronisch erzeugte und gespeicherte Daten / elektronische Signaturen ist die 21 CFR part 11-Compliance notwendig.

    Im Mittelpunkt: Dokumentation und Records Management

    Die Computersysteme sind in den letzten Jahren immer stдrker in die Sammlung, Prozessierung, Speicherung und Archivierung von Daten entlang der Wertschцpfungskette der Unternehmen eingebunden. Darьber hinaus sind die IT-Systeme auch ein integraler Bestandteil von automatisierten Prozessen in Labor und Produktion. Die Bandbreite der vorhandenen Systeme ist groЯ: Arbeitsplatzrechner und rechnergesteuerte Instrumente sowie LIMS (Laboratory Information Management Systems) in regulierten Umgebungen, Datenarchivierung und -Speicherung bis hin zu Produktionssteuerungs- und Prozessleitsystemen. Billing- und Chargen-Informationen bilden die Grundlage des unternehmensweiten Controllings in der pharmazeutischen ebenso wie in der chemischen Industrie.

    Allen Compliance-Themen ob nun fьr Pharma-Hersteller und deren Zulieferer (FDA, GMP etc.), die chemische Industrie entlang der gesamten Supply-Chain (REACH) oder den von Finanzbehцrden geforderten (SOX, GDPdU) – ist eine Verpflichtung gemeinsam: Daten und Dokumente in der IT-Infrastruktur mьssen nach fest definierten Workflows sicher vor Manipulationen und nach festgelegten Kriterien langzeitarchivierbar verwaltet werden. Im Zentrum der Compliance steht also primдr ein audit- und revisionssicheres Daten- und Records Management auf allen Ebenen.

    Es gibt Lцsungen zur Erreichung eines FDA-konformen Daten- und Records Managements, die einfach, kostengьnstig und schnell implementierbar sind. Diese zeichnen sich durch die problemlose Integration in die bestehende Office-Welt des Unternehmens und die Unterstьtzung aller Intranets, Extranets und Webanwendungen (Collaboration) aus. Backend-Systeme wie z.B. Laborgerдte, PLS, LIMS, SAP, Oracle, Daten aus Mailingsystemen usw. lassen sich einfach einbeziehen. Fьr Projekte zur Erreichung einer Compliance gleich ob FDA/GMP, REACH oder finanzgetriebene Themen werden Projektfortschritt und status ьbersichtlich in einem Management-Dashboard dargestellt, fehlende Dokumente und GAPs angezeigt. Die Integration beliebiger Backend-Systeme sowie die Einbindung bereits vorhandener, auch heterogener Systeme ist mцglich. Ebenso kann eine Compliance-Lцsung auf weitere Records, kьnftige Regularien und andere Compliance-Bereiche erweitert werden.

    Wesentliches Qualitдtskriterium dabei ist die Projektdurchfьhrung: Bei der Lцsungsfindung und deren Implementierung gilt es zu beachten, dass in der Planungsphase Regelungsumfang und -inhalte sowie die Vorgehensweise unternehmensspezifisch geklдrt werden. Die betroffenen Systeme mьssen daraufhin inventarisiert, der erstellte Fragenkatalog samt Auswertungen abgearbeitet werden. Die Anforderungen sollten zusдtzlich in Testszenarien ьberprьft und in einem Projektplan dargestellt sein. Bei der Umsetzung sind Risikoanalysen der einzelnen Infrastrukturbereiche unabdingbar. Die Herstellung der Compliance wird ergдnzt durch die notwendigen Zertifizierungen, Mitarbeiterschulungen und ein begleitendes Qualitдtsmanagement wдhrend der gesamten Projektlaufzeit. Mit dieser Verbindung von System- und Prozessanalyse, Implementierung und Validierung lassen sich die unternehmensspezifischen Anforderungen bestimmungskonform realisieren: Risiken und Nebenwirkungen sind zum Wettbewerbsvorteil geworden.

    Charakteristika einer erfolgreichen FDA-Compliance-Lцsung

    • Erfьllung der regulatorischen Anforderungen fьr ein audit- und revisionssicheres Daten- und Records Management,
    • schnelle und individuelle Anpassungsmцglichkeit an Unternehmens-Prozesse und -Ziele unter Compliance-Aspekten
    • Anbindung beliebiger Backendsysteme
    • Bereitstellung von Tools und Werkzeugen fьr regularienkonforme Collaboration und Datenaustausch
    • modulare Erweiterungsmцglichkeit auf andere Compliance-Themen





    US Pharma’s Financialized Business Model, italian pharmaceutical companies.#Italian #pharmaceutical #companies

    Navigation

    Italian pharmaceutical companies

    Explore by

    US Pharma’s Financialized Business Model

    Working Paper Series By

    • Italian pharmaceutical companies

  • Italian pharmaceutical companies

    • Senior Researcher, The Academic-Industry Research Network

  • Italian pharmaceutical companies

    • Professor of Economics, Paris 13 University

  • Italian pharmaceutical companies

    • Research Associate, The Academic-Industry Research Network (theAIRnet)

    Price gouging in the US pharmaceutical drug industry goes back more than three decades.

    In 1985 US Representative Henry Waxman, chair of the House Subcommittee on Health and the Environment, accused the pharmaceutical industry of “gouging the American public” with “outrageous” price increases, driven by “greed on a massive scale.” Even in the wake of the many Congressional inquiries that have taken place since the 1980s, including one inspired by the extortionate prices that Gilead Sciences has placed on its Hepatitis-C drugs Sovaldi since 2013 and Harvoni since 2014, the US government has not seen fit to regulate drug prices. UK Prescription Price Regulation Scheme data for 1996 through 2010 show that, while drug prices in other advanced nations were close to the UK’s regulated prices, those in the United States were between 74 percent and 181 percent higher. Médecins Sans Frontières (MSF) has produced abundant evidence that US drug prices are by far the highest in the world.

    The US pharmaceutical industry’s invariable response to demands for price regulation has been that it will kill innovation. US drug companies claim that they need higher prices than those that prevail elsewhere so that the extra profits can be used to augment R ?>

  • Aspire Pharmaceuticals, pharma management.#Pharma #management

    Pharma management

    Pharma management

    Pharma management

    Pharma management

    Welcome To Aspire

    Aspire Pharmaceuticals is a global leader in soft gelatin manufacturing. Our stringent procurement operations backed with rigorous analytics and testing infrastructure provides custom solutions for our clients from concept to delivery. We are here to guide our clients to innovate better all while optimizing their product journey. As industry trailblazers we are constantly looking to think beyond the status quo.

    About Us

    Our Mission

    As a leader in the development and manufacturing of soft gelatin nutritional supplements, we take that role with pride. Our singular vision starts with a question. How can we do it better? This sense of wonder is our driving force to create the highest quality products in the industry. No matter how the process starts, we always go through extensive testing studies, and refinement resulting in a superior encapsulated product.

    Our Capabilities

    Our Focus

    Innovate. Formulate. Encapsulate. As our mantra suggests we are focused on innovation. We strive to revolutionize soft gel manufacturing and are determined to always be improving our own capabilities- from enhancing our cGMP lab to employing the use of robotics and vision camera inspection on the production floor. As a center of excellence for encapsulation we know how to consistently optimize the process all while providing our clients with the best possible products.

    Quality Standards

    Pharma management

    Packaging Options

    Pharma management

    Testing Infrastructure

    Pharma management

    Our Products

    Where We Shine

    We offer custom softgels in any size, shape and color. From one-ingredient oils to complex multi-ingredient fills, every step of the capsule manufacturing process has up-to-date standard operating procedure guides and adheres to the Good Manufacturing Practices put forth by the US Food and Drug Administration.

    Coconut Oil

    Pharma management

    Dark Yellow Gel

    Pharma management

    Orange Oval Gel

    Pharma management

    Research And Development

    How Quality Is Created

    Our research and development team has decades of pharmaceutical experience. Our talented teams of formulators, chemists, and PhDs have extensive experience in nutritional, biological, and pharmaceutical sciences. All products are researched, created and tested within Aspire’s cutting-edge cGMP lab. Our team fulfills product development objectives while providing analytical method validation and release testing on feasibility, stability and clinical batches.

    Why Softgels

    Gelatin capsules are easily digested and dissolve within minutes of reaching the stomach, We also have our propriety GelMelts™ formulation which guarantees accurate dosage, is available in liquid or paste formulations and delivers a convenience, taste and great mouth. All of our softgel products can be formulated using 100% natural ingredients. Our team is always ready for collaboration to deliver your ideal product, whether you’re working through the R ?>

    MT – Medical Transcription, Work at Home Business, and Career Tips, thompson pharma.#Thompson #pharma

    thompson pharma

    Thompson pharma

    Thompson pharma

    Thompson pharma

    Thompson pharma

    Human Anatomy Images and Diagrams

    Most Common Drugs

    Medical Transcription Services

    Normal Lab Values

    Calendar of Events

    Thompson pharma

    Thompson pharma

    HOW LONG WILL IT TAKE?

    Thompson pharma

    Thompson pharma

    Thompson pharma

    Thompson pharma

    Thompson pharma

    Thompson pharma

    Thompson pharma

    Thompson pharma

    Thompson pharma

    Medical Transcription is one of the fastest growing home-based professions in the country. The demand for qualified medical transcriptionists continues to accelerate, creating unprecedented financial and career opportunities for individuals who have the skills to succeed in the fast paced environment of medical transcription.

    Medical transcription offers far more than a fabulous career. It offers a unique lifestyle that many dream of, but most fail to achieve because of uncertainty or lack of motivation.

    Medical transcription can be technically challenging. However, medical transcription can also be extremely rewarding. If you are serious about exploring a career as an at home medical transcriptionist, it will be important to find the right medical transcription school.

    Find out how to train at home to work at home as a medical transcriptionist. There is no time like the present to begin on this rewarding new work at home career!

    Thompson pharma

    Thompson pharma

    Learn what it takes to start your own successful small business. Recognize and avoid common pitfalls and grow your business profitably from the very beginning.

    Thompson pharma

    Thompson pharma

    Take a breather and share a laugh with us. A whimsical look inside the sometimes comical and frequently unpredictable home-based office.

    Thompson pharma

    Thompson pharma

    We’ve circled the globe in search of the best popcorn recipes on the planet. There’s certain to be a popcorn recipe to suit your mood. Hot, spicy, sweet, chewy, nutty, sticky. you get the idea. Enjoy!

    Thompson pharma

    Thompson pharma

    Dust off that old view-master and click your way through MT World’s Random Image Gallery. Hundreds of images for hours of viewing pleasure.

    Thompson pharma

    Thompson pharma

    Are you making the most of your career? Learn to unleash your full career potential and receive the rewards you deserve.

    Thompson pharma

    Thompson pharma

    Dress code for the new millennium. Tips on how to ensure a professional appearance in today’s dynamic work environment.

    Thompson pharma

    Thompson pharma

    In today’s fast paced world it can be difficult to find time for family. Why not give your kids some income and experience while you take advantage of a great tax write-off?

    Thompson pharma

    Thompson pharma

    Step into the zany and often out-of-control world of Mr. Jones as he bumbles his way through some of the most outlandish career situations.

    Thompson pharma





    Tablet Line Equipment, pharma equipment.#Pharma #equipment

    Innovating with Passion

    FOR OVER 50 YEARS!

    Pharma equipment

    PACK EXPO Las Vegas

    September 28-30, 2015

    Pharma equipment

    ACHEMA-World Forum and 31. Leading Show for the Process Industries

    Frankfurt am Mein, Germany

    Pharma equipment

    Anaheim Convention, Anaheim, CA

    February 10-12, 2015

    Pharma equipment

    Messe D ssseldorf, D sseldorf, Germany

    Pharma equipment

    Anaheim Convention, Anaheim, CA

    February 11-13, 2014

    SEMI-AUTOMATIC EQUIPMENT

    Filling | Plugging/Stoppering | Crimping/Capping | Labeling

    INLINE FILLING SYSTEMS

    Gravity | Pressure | Vacuum | Volumetric | Mass Flow

    PLUGGING CAPPING SYSTEMS

    Inline Belt-Driven | Chunk style | High Speed Rotary

    MONOBLOCK SYSTEMS

    Filling | Plugging/Stoppering | Crimping/Capping | Labeling

    TABLET LINE EQUIPMENT

    Counting | Desiccant (sachet /canister) | Cotton inserting Outsert (Top/side)

    LABELING SYSTEMS

    Inline | Rotary | High Speed Rotary

    OPTIONAL EQUIPMENT

    Unscrambler | Rinser | Banding | Accumulation

    INDUSTRY SOLUTION

    Cosmetic |Perfume |Pharmaceutical |Nutraceutical

    Biotech |Food beverages etc.

    tablet line equipment

    Street Fighter

    The Countlab’s Street Fighter series electronic tablet and capsule counters exceed cGMP specifications and increase production efficiency. The Street Fighter tablet and capsule counters are designed to handle tablets, caplets, hard caps, and softgels etc. A wide range of container sizes and shapes can be accommodated. Changeover time is minimized through keyed parts and latching mechanism. The Street Fighter tablet and capsule counters have been configured to maximize production efficiency and simplify the packaging process. In comparison to current standard of the same class, the SF series are compact while providing a greater throughput. Additional benefits include reduced parameter settings, modular design, programmable recipes, and 21 CFR part 11 ready.

    More Information, please visit Countlab ‘s official website: http://www.countlab.com

    Applications: Tablets | Caplets | Hard Caps | Softgels Speed*: Up to 120 BPM**

    * Speed and performance criteria is subject to testing with actual samples. ** BPM:Bottles Per Minute

    SorbStar

    SorbStar is capmatic’s new designed sachet or canister desiccant inserter.

    The frame of new SorbStar is made of anodized aluminums with structure completely covered with stainless steel. Electrical and mechanical parts are located inside the machine frame for a complete protection. Bottle is indexed by servo driven in-feed worm mechanically synchronized with the dispenser and bottle changeover can be done very quickly and without the use on any tool.

    Desiccant delivery confirmation sensor;

    No bottle – No desiccant;

    Back up sensor at in-feed and out feed of filling machine with automatic restart;

    Stainless steel panel control with strong stainless steel tubular holding post;

    Allen Bradley PLC & HMI;

    Self-teach optics and advanced self-threading make setup quicker and easier;

    Eye registration – a fibre optic sensor will locate a register mark to cycle the machine;

    Embedded optics on blade bracket to improve accuracy;

    * Speed and performance criteria is subject to testing with actual samples. ** BPM:Bottles Per Minute





    List of Government and Private Pharma Colleges in India, pharma suppliers.#Pharma #suppliers

    Pharma Colleges in India

    Pharma suppliers

    Pharma suppliers

    Pharma Colleges Directory

    To get full information about 700+ Pharma Colleges from India.

    Pharma suppliers

    Sample Data

    Pharma suppliers

    This product covers all essential information that include the following details:

    Other Details

    You May Also Like

    Pharma suppliers

    Outsmarting the Cancer’s Immunosuppression

    Pharma suppliers

    Astrocytes Play an Important Role in Neuronal Development, Says Study

    Pharma suppliers

    Greater Pressure Drops in Hypertensive Patients Lowers Kidney Function

    Pharma suppliers

    Phone-Based Videomicroscope Useful to Treat River Blindness

    Search By State

    Colleges

    Pharma suppliers

    Medical Colleges

    Pharma suppliers

    Dental Colleges

    Pharma suppliers

    Nursing Colleges

    Pharma suppliers

    Pharma Colleges

    Pharma suppliers

    Ayurveda Colleges

    Pharma suppliers

    Homeopathy Colleges

    Pharma suppliers

    Siddha Colleges

    Pharma suppliers

    Unani Colleges

    Medindia Newsletters

    Subscribe to our Free Newsletters!

    Pharma suppliers

    Student – Quick Links

    Stay Connected

    What’s New on Medindia

    Pharma suppliers

    State Health Insurance Programs

    The state health insurance programs provide health care support to the below poverty line (BPL) .

    Pharma suppliers

    Pleurectomy – Surgical Procedure

    There is a lining between the lungs and chest wall known as Pleura. The dismissal of pleura by a .

    Pharma suppliers

    Vesicoureteric Reflux and Reflux Nephropathy

    Reflux nephropathy is the scarring and damage caused to the kidneys by reverse flow of urine from .

    Follow Us On :

    Disclaimer – All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.

    Pharma suppliers





    Bertin Pharma: Research Solutions – Bioanalytical Tools – Bertin Pharma, pharma bio.#Pharma #bio

    Bertin Pharma Pharma bio

    Pharma bio

    Pharma bio

    Pharma bio

    Pharma bio

    Pharma bio

    Pharma bio

    By continuing your navigation without changing your cookie settings, you accept the use of cookies. Know more

    Bertin Pharma focuses its activity on providing Bioreagents and Bioanalytical Tools.

    Our Solutions for your Drug success: Browse Play!

    4 reasons to start online buying experience among +20K refs!

    Bertin Pharma is a leading comprehensive solution provider, offering Research Solutions Services along with Bioreagent Tools.

    Your fields of expertise are Pharmaceutics, Biotechnologies, Cosmetics or Nutraceutics. With you, we work hard to create a healthier world.

    We propose pioneer offers thanks to our innovative technologies, dedicated technical platforms environments with adequate standards (GLP, GMP, GDP). For us, everyday is a new page of innovation.

    For us, everyday is page for innovation.

    Our clients have a worldwide scope, but our deep belief is that the key of success belongs to a human scale. A single Project Manager coordinates a team of experts dedicated to the success of your project

    Our solutions

    We offer turnkey solutions so that your daily search is smooth.

    Contact us

    Call us or email us for any question you may have on the best product to select regarding your research, assistance regarding your results. Just contact us and we are by your side.

    About us

    We supply with high quality products coming from either most cutting-edge technologies or in-house development. We also advise and accompany your during your experiment with our dedicated customer care.

    Bioreagents

    • Pharma bio

  • Pharma bio

  • Pharma bio

  • Pharma bio

  • Pharma bio

  • Pharma bio

  • Pharma bio

  • Pharma bio

  • Pharma bio

    Research Solutions

    • Pharma bio

  • Pharma bio

  • Pharma bio

  • Pharma bio

  • Pharma bio

  • Pharma bio

    Pipeline products for Out-licensing

    • Pharma bio

  • Pharma bio





  • Bio Pharma Giant – Celgene – Settles Case Alleging Marketing Violations For $280 Million, pharma

    Bio Pharma Giant — Celgene — Settles Case Alleging Marketing Violations For $280 Million

    News provided by

    Jul 25, 2017, 17:08 ET

    Share this article

    LOS ANGELES , July 25, 2017 /PRNewswire-USNewswire/ — On the eve of trial, Bio Pharma giant, Celgene Corporation, has agreed to pay $280 million to resolve allegations it sold and promoted its blockbuster drugs, Thalomid and Revlimid, in violation of federal and state laws.

    The case, U.S. ex rel. Brown v. Celgene, CV 10-03165 (RK) ( C.D. Cal .), was brought by a former Celgene sales representative, Beverly Brown , under the federal False Claims Act (FCA) and state analogues. The federal civil settlement agreement encompasses allegations Celgene: (1) promoted Thalomid and Revlimid for off-label uses that were not approved by the FDA, were – in many cases – unsafe, and were not properly reimbursable by federal insurance programs; and (2) offered illegal kickbacks to a wide range of entities in an effort to influence health care providers to select its products for use, regardless of whether they were reimbursable by federal or state health care programs or were medically necessary. The settlement also encompasses allegations that Celgene: (1) concealed or downplayed adverse events associated with use of Thalomid and Revlimid; and (2) improperly influenced the content of published drug compendia entries, medical literature, clinical studies and NCCN guidelines for Thalomid and Revlimid to support uses of these drugs not supported by medical science, including by making payments to physicians who had influence over the content of published drug compendia entries.

    Ms. Brown brought her case in 2010 and it remained under seal – and under investigation by the government for 4 years – until 2014 when the government decided not to pursue the case.

    Pursuing the case on her own, the $280 million resolution marks the second largest recovery in a non-intervened FCA case, largest recovery against a pharmaceutical company in a non-intervened case where core allegations were based on off-label promotion, and largest recovery involving a manufacturer of cancer drugs.

    Originally passed by Congress and signed into law in 1864, modern day federal and state false claims acts allow whistleblowers – known as “relators” – to bring suit in the name of government against individuals or entities that caused the fraudulent or improper expenditure of government monies.

    The litigation involved the review of millions of documents, briefing of numerous discovery motions and potentially case dispositive motions, taking of roughly 40 depositions, and analysis by leading medical experts, pharmaceutical economics experts, and conflicts of interest and medical ethics experts. Celgene alone tendered 13 experts. This undertaking makes this one of the most extensively litigated pharmaceutical cases brought under the FCA.

    At the culmination of the discovery period, on December 28, 2016 , the United States District Court in Los Angeles (Judge George King ) issued an order denying summary in part, allowing the case to proceed to trial against Celgene on claims of off-label promotion.

    In his Opinion, Judge King noted that “Celgene understood that its promotional efforts were successful in causing physicians to write prescriptions.” The Opinion also said that “hundreds of thousands of claims for off-label uses of Thalomid and Revlimid were submitted to Medicare and other government programs during the time when Celgene was promoting these drugs off-label.”

    “In an era where drug prices are out of control and too many people are prescribed unnecessary medications, cases like Celgene function as critical oversight of industry which purportedly serves a healthcare function but way too often is driven by Wall Street goals, said Reuben Guttman , of Guttman, Buschner Brooks PLLC (GBB) and counsel to Beverly Brown . His partner, Justin Brooks , added that discovery in the case identified new paradigms for pharmaceutical fraud that will influence investigation and litigation of future False Claims Act cases.

    In addition to GBB, the Brown litigation team included the firms of Bienert, Miller Katzman (“BMK”) of San Clemente California , Richard A. Harpootlian , P.A. of Columbia, South Carolina , and former federal Judge and Harvard Law Professor, Nancy Gertner , from Boston , Massachusetts. Their work was instrumental to the case’s success.

    GBB lawyers on the case include firm partners Reuben Guttman , Traci Buschner , and Justin Brooks as well as Of Counsel Dan Guttman , Liz Shofner , Caroline Poplin , MD/JD, and Paul Zwier , who is also an evidence expert and Professor at Emory Law School.

    Richard Harpootlian and Chris Kenney were the principle counsel on the case from Richard A. Harpootlian , P.A. Tom Bienert , Mike Williams , Ariana Hawbecker , and Ali Matin were the principal lawyers from BMK.

    For attorneys at Guttman, Buschner Brooks PLLC, the settlement marks another positive result in a string of cases under the False Claims Act. With the addition of this settlement, GBB attorneys have represented whistleblowers in cases recovering nearly $5.5 billion for the federal government and state governments.

    This action also marks another significant recovery for Richard A. Harpootlian , P.A., which holds the record for the largest bounty paid to a relator in a South Carolina whistleblower action and has recovered hundreds of millions of dollars for federal and state governments.

    Bienert, Miller Katzman, PLC (BMK) is a trial firm that was uniquely qualified to work with the other firms in this case. Consisting of former federal and state prosecutors, federal public defenders and large firm trained attorneys, its lawyers collectively have hundreds of jury and court trials. The result in this case marks a string of multi-million dollar trials and settlements for its clients. BMK continues to advocate for a number of significant whistleblower suits, combining nationally recognized expertise in a boutique legal setting, ensuring personalized attention to their cases.





    Big Pharma funded anti-US militia in Iraq, US veterans allege in lawsuit, Fox News, pharma

    Big Pharma funded anti-US militia in Iraq, US veterans allege in lawsuit

    Pharma equipment

    Major drug makers helped fund Iraqi militias that attacked U.S. troops, a lawsuit alleged Tuesday. Pictured: Iraqi military forces engage in operations in an undated photo. (Associated Press)

    U.S. and European drug companies indirectly yet knowingly funded Iran-backed Iraqi militias that carried out attacks against U.S. troops, veterans of the Iraq War alleged in a lawsuit filed Tuesday.

    The lawsuit alleges that five drug companies won contracts with the Iraqi government during the 2003 peak of the war with knowledge that free drugs and medical devices would end up in the hands of a Shiite militia.

    That militia would then sell the drugs and devices to the black market to fund its operations against the U.S., the New York Times reported.

    Named in the lawsuit are U.S. firms General Electric, Johnson Johnson and Pfizer and European drugmakers AstraZeneca and Roche Holding A.G.

    The companies won contracts with the Iraqi Ministry of Health that at the time was controlled by the leader of the Mahdi Army, a group known for attacking U.S. troops and working closely with Lebanese paramilitary group Hezbollah, which the U.S. has designated a terrorist group, the Times reported.

    The group was known as the “Pill Army,” according to the Financial Times, as some of the fighters were known to have been paid in drugs rather than cash.

    The budget for Iraq’s health ministry skyrocketed from $16 million in 2003 to more than $1 billion in 2004 following the influx of aid from the U.S.

    To win the lucrative deals with the ministry, the companies allegedly paid bribes in the form of “free goods” – amounting to as much as 20 percent of the contract value, according to the suit, USA Today reported.

    The Iran-backed militia then allegedly sold the free drugs and medical devices to the black market – providing an important source of income to carry out attacks against U.S. troops, the lawsuit alleges.

    Between 2004 and 2013, the companies allegedly also created a “slush fund” that was created to pay for after-sales support but in reality went to the pockets of officials at the ministry, providing another source of income to the militia, according to the Financial Times.

    The suit cites contracts between the Iraqi government and the companies, leaked reports, press accounts and testimony of informants as evidence of wrongdoing.

    The legal challenge is waged by attorneys from a firm led by Ryan Sparacino and the litigation firm of Kellogg Hansen. The suit was filed by a group of military veterans and their family members according to a law that allows U.S. citizens injured by terrorism to seek damages. More than 100 plaintiffs are included in the lawsuit.

    “While Americans worked to rebuild Iraq, many were attacked by a terrorist group that we allege has been funded in part by the defendants’ corrupt sales practices,” Josh Branson, a Kellogg Hansen partner, told the Times.





    Pharmaceutical Formulation Manufacturer, Veterinary Medicines Supplier, WHO GMP Certified Company In Mumbai, pharma drugs.#Pharma #drugs

    Healthy Life Pharma Private Limited

    Healthy Life Pharma (P) Limited is acknowledged world wide at pharma horizon, providing a broad range of pharmaceutical formulation to cope with the necessity of ailing humanity. With its headquarter at Mumbai (India), Healthy Life Pharma holds expertise in offering different formulations that include injection, tablets, capsules, liquid, dry syrups, pre filled syringes, ointments etc.

    Healthy Life Pharma (P) Limited is the flagship company of Shah Group, founded by Mr. Shah in 1976. An encouraging leader and inspiring personality, Mr. Shah has continuously looked forward to shape the group companies into huge and dynamic enterprise.

    Having three decades of experience, Healthy Life Pharma is a WHO recognized organization, which has certifications for cGMP and ISO 9001:2000 from UKAS for productive management in developing, quality control and operations. The firm has operations in Indian and global markets as well, where its business is spread in more than 30 countries. An innovative global pharmaceutical entity, we are engaged in continuous R ?>

    A new wave of pharma mergers could put innovative drugs in the pipeline, pharma drugs.#Pharma

    A new wave of pharma mergers could put innovative drugs in the pipeline

    By Michael S. Ringel and Michael K. Choy

    Pharma drugs

    new wave of pharmaceutical industry mergers may be on the horizon, driven in part by the $1.3 trillion in overseas cash that U.S. corporations currently hold. If policymakers provide a tax holiday on repatriation of these funds, some experts say that U.S. pharmaceutical companies would be flush with cash and could likely spend a meaningful portion of this windfall on mergers.

    While big mergers could have many impacts — on employment at home and abroad, competition, and drug prices, to name a few — one of the most important would be the effect on research and development productivity and innovation.

    Analysts have tackled this topic before. Their work has been of mixed quality and, perhaps not surprisingly, has yielded mixed results. Pundits at the Institute for Competition Economics in Dusseldorf, Germany, for example, claimed last year in a Harvard Business Review article that previous drug company mergers had “substantially” reduced R D and innovation, not only at the merging firms but at the merging firms’ competitors as well.

    Another team, this one from Duke University, the University of Toronto, and Baruch College/CUNY, reached a different conclusion with its data-driven approach. The team’s review of hundreds of mergers and acquisitions from 1985 to 2009, published in Loyola University Chicago Law Journal, indicated that the correlation between merger and acquisition activity and FDA approvals of new drugs is “moderately positive,” both at an industry level and individual firm level.

    Who’s right? Are those in need of new lifesaving drugs harmed by consolidation in the pharmaceutical industry, or are they helped?

    We believe that one of the main problems with much of the previous research in this area has been an over-reliance on anecdotal reporting rather than employing systematic data analysis. Even when such analysis has been done, researchers have sometimes focused on research and development spending or patent activity as benchmarks of success, as if these metrics are indicators of — or even synonymous with — actual product innovation.

    But they aren’t necessarily the same. Spending is just an input, measured in dollars or some other currency. The same is true with patents. There is a long distance between the laboratory where new compounds are discovered and the corner drugstore where medicines are purchased.

    We sought to address this uncertainty by focusing on research and development productivity: the amount of innovation created as measured by the value of new FDA-approved compounds reaching the pharmacy, relative to input. After all, what matters to patients is the creation of quality medicines, not how much a company spends on research and development or the number of patent applications it files.

    To determine whether mega-mergers benefit patients, we looked at what happened to research and development productivity in all of the major mergers going back to 2001, including the last big wave in 2009 that brought together Merck Co. and Schering-Plough, Pfizer and Wyeth, and Roche and Genentech.

    As expected, the results varied from year to year and company to company. But our report in Drug Discovery Today showed that mergers generally appeared to drive productivity up — and did so significantly.

    Why might this be so? While mergers undoubtedly bring disruption to research and development, they also can be catalysts for addressing the fatal flaw of most research and development enterprises: the high cost of failure.

    More than 90 percent of pharmaceutical industry spending on research and development goes into projects that never reach the market. Any intervention that helps reduce this waste can be a real boon to productivity.

    There are really only two ways to fix the industry’s cost-of-failure problem: 1) start with better science, so you have fewer failures; and 2) employ better decision-making about when to stop projects so you can reallocate that capital to more-promising opportunities.

    Mergers can help with both of these dimensions. They bring the best combined science of the merged organizations to bear on the difficult questions of which pathways, modalities, and molecules to pursue. Mergers also trigger reviews that drive the leadership of the new company to take a fresh look at research and development. These reviews can offer the leadership an opportunity to soberly and objectively reassess its scientific hypotheses in each disease area and reevaluate the combined research and development portfolio, eliminating those projects least likely to produce advances in treatment.

    This spring cleaning can have a cathartic effect. The combination of the two factors — fresh science and a fresh look at the portfolio — can create a renewed research and development enterprise better able to bring new medicines to patients.

    Our analysis doesn’t suggest that all mergers are good. Even from the perspective of research and development productivity, some mergers in our study appeared to have depressed the flow of new medicines to patients by slowing down or stopping promising projects. And there are considerations beyond the scope of our analysis, such as jobs or drug prices, that may be equally valid inputs to views about mergers and acquisitions.

    Overall, however, the evidence indicates that large mergers increase, not decrease, the productivity of pharmaceutical research and development — good news for those in need of new therapies.

    Michael S. Ringel is a Boston-based senior partner of The Boston Consulting Group and global leader of its research and product development topic. Michael K. Choy is a New Jersey-based partner at BCG. Both work in the firm’s health care practice area, which funded the research for this article.





    Is the NHS being held to ransom by big pharma, noel pharma.#Noel #pharma

    Is the NHS being held to ransom by big pharma?

    L ate last year Britain’s competition watchdog slapped a record £90m worth of fines on US drugs giant Pfizer, and British manufacturer Flynn, for jacking up the price of an anti-epilepsy pill by more than 2,000pc.

    To critics of big pharma, it was a clear and egregious example of “price gouging” – hiking the price of a product in a market you dominate in order to rake in big profits.

    But for Pfizer and Flynn – who embark on an appeal against the decision later this month – it was a justified increase to ensure continued supply of a drug they claim had previously been loss-making.

    As the arguments are heard at the Competition Appeal Tribunal in the coming weeks, it will once again shine an uncomfortable light on the tension between drug makers and the health service over rising medicine prices.

    But one place this battle will not be played out is at the High Court, after it this week threw out a judicial review challenge by industry trade body the Association of the British Pharmaceutical Industry (ABPI) against NHS drug pricing powers.

    T hese powers enable the health service to ration the use of medicines expected to cost more than £20m in any of their first three years of use – something the ABPI complained would limit patients’ access to cutting-edge treatments.

    H owever the challenge came to nothing and the ABPI said it would not appeal against the decision. None the less, both clashes bring into sharp focus the question of whether patients get a fair deal on drug prices. Is big pharma ripping us off? Or should we spend more on drugs?

    It’s an issue that divides drug firms and policymakers. The industry points to various indicators suggesting British patients are getting a raw deal as public bodies try to save on the nation’s £15bn medicines bill while arguably not prioritising access to the latest life-saving therapies.

    Dr Richard Torbett, executive director of the ABPI, says: “If we look at comparable countries, Britain pays some of the lowest prices for medicines but has some of the lowest access – meaning patients ultimately miss out.” The Government’s own competitiveness indicators show that for every 100 patients in France, Spain and Germany that get access to a medicine in the first year after approval, just 18 get it in the UK.

    Meanwhile, the ABPI’s cancer comparator report in July, endorsed by Cancer Research UK, found that on average British patients had lower levels of access to six leading cancer medicines than EU counterparts.

    D rug makers say they also have an agreed system in place with the Department of Health to cap increases in the lion’s share of NHS’s overall branded medicines bill to no more than 1.1pc a year. The system has resulted in more than £2bn being rebated since 2014. But it does not cover all medicines and is up for renewal in early 2019.

    C rucially it also does not cover so-called “generic medicines”, where a drug’s patent has run out, allowing firms to increase its price through a process known as “debranding”.

    Noel Wardle, at law firm Charles Russell Speechly, believes the “debranding” process lets the sector down. “If you view the market as a whole then the NHS gets a good deal in terms of medicine prices,” he says.

    “But there are anomalies that create headlines and cause concern where money is spent unnecessarily.”

    It was a generic drug, anti-epilepsy medicine Epanutin, that got Pfizer and Flynn in hot water with the Competition and Markets Authority (CMA). Once a patent has run out, a loophole in regulations allows firms to work with a distribution partner to rebrand it and increase its price.

    The price of Epatunin, phenytoin sodium capsules used to control seizures in 50,000 patients, went from £2.83 per pack to £67.50 overnight.

    I n a year the NHS’s bill for the same product leapt from £2m to £50m when all that changed was the name and the method of distribution.

    Pfizer is committed to appealing against “all aspects” of the CMA decision but declined to go into detail.

    The US firm stressed the drug had been “a loss-making product” and the deal with Flynn “represented an opportunity to secure ongoing supply of an important medicine for patients with epilepsy, while maintaining continuity of supply”.

    I t also said the retail price for Epatunin was set at up to 40pc less than an equivalent product, although the hard tablet form indicated, critics say, is not a strict equivalent given doctors are reluctant to change prescriptions to even different forms of the same drug for epilepsy sufferers given the delicate brain chemistry at play. Flynn declined to comment.

    The CMA fines for Pfizer and Flynn came ahead of a change in law in April designed to help close the loophole.

    Once enforced, it will make firms submit detailed figures for how much it costs to manufacture a drug and the profit being made on it, with government given powers to claw back profits it deems as excessive.

    But its implementation has been delayed due to lack of parliamentary time following the snap election, summer recess and party conference season. A consultation is finally expected to begin next month ahead of the powers starting in early 2018.

    In the meantime, the Sunday Telegraph has seen evidence that the practice of steep drug price rises through the “debranding” route is still happening. Ben Merriman, a pharmacist from Cumbria who sits on a local NHS commissioning group, says he has identified around 90 drugs over the last few years that have had steep price increases through debranding that he believes were for “no good reason whatsoever”.

    “The practice is still going on and it’s a big issue costing the NHS hundreds of millions of pounds a year,” he says.

    C harles Russell Speechly’s Wardle says the problem with “debranding” price hikes is that firms can get away with price increases where they effectively hold a monopoly on that therapy area. “There’s not usually the competitive tension that drives down prices. So they can inflate the price of these products.” He says the new regulations coming through “will have teeth” but acknowledges there is a risk the transparency regime could be open to manipulation due to its reliance on firms disclosing cost and profit figures. On the wider picture of overall and branded drug prices the debate will rage on. The ABPI said this week after its High Court challenge fell through that working with government and the NHS “we must now focus on finding real, workable solutions to help NHS patients get fast access to the medicines they need”.

    But the backdrop is of rising costs for next generation treatments, including personalised and genetic therapies for diseases like cancer, putting potentially more pressure on the health service.

    Policy specialists point to studies suggesting the NHS already pays excessively for drugs, including a University of York research paper two years ago that concluded the health service should get better value.

    D rug pricing pressure is an issue that’s here to stay. But the Government has a chance to help stamp out “price gouging” if it can only roll-out the new powers it has decided on quickly.





    Facult – de Pharmacie, noel pharma.#Noel #pharma

    Bienvenue sur le portail de la Facult de Pharmacie

    La Facult de Pharmacie est une Facult innovante et moderne, qui propose trois ann es de Bacheliers et deux ann es de Masters en sciences pharmaceutiques.

    Des Stages professionnels compl mentaires (1,5 mois) sont int gr s la 5 me ann e (bloc 2 du Master) : orientation officine, h pital, industrie, pharmacie clinique, analyse biologique, recherche, coop ration, etc.

    La Facult propose galement :

    Un apprentissage dynamique, sous forme de projets transdisciplinaires interprofessionnels, comme par exemple le Projet Edupharm en Master.

    Des programmes d changes Erasmus (Espagne, Italie, . ).

    Des services et des possibilit s d’acc s une plateforme analytique pour des analyses ou des formulations.

    Un dipl me d Agr gation de l’enseignement secondaire sup rieur en sciences pharmaceutiques.

    Un Certificat d’aptitude p dagogique appropri l’enseignement sup rieur en pharmacie.

    La situation d’Hamid se d t riore

    Alors qu’il aurait d j d tre lib r en ao t 2015, depuis le 30 juillet dernier, suite des violences qui ont t commises son encontre, Hamid a entam une gr ve de la faim. Son tat de sant est pr occupant. Signez la nouvelle p tition pour le soutenir.

    Noel pharma

    Franc succ s pour le Relais pour la vie 2017!

    Noel pharma

    Comme chaque ann e, ces 14 et 15 octobre, l’ULB courait en quipes dans le cadre du Relais pour la vie organis par la fondation contre le cancer, afin de rendre hommage au combat quotidien des Battants, de saluer la m moire des victimes de cette maladie mais aussi de collecter des fonds pour financer la recherche.

    L’ quipe de notre Facult s’est particuli rement distingu e. Non seulement parce qu’elle est l’ quipe facultaire a avoir r uni la somme la plus importante cette ann e. Mais surtout gr ce sa participation active qui a t applaudie par les organisateurs. Sa pr sence, tout au long du weekend, de jour (stand scientifique) comme de nuit (animation assur e par le Cercle CePha et le BePha) a t particuli rement appr ci e.

    Notre Doyen remercie Etudiant.e.s, Ancien.ne.s et Membres du personnel qui ont contribu ce succ s par leurs dons, leur aide et leur pr sence.

    Papillomavirus et cancer du col de l’ut rus: des lymphocytes impliqu s

    Noel pharma

    Une population de cellules immunitaires peu connues favorisent le cancer du col de l ut rus provoqu par le papillomavirus. Une tude men e conjointement par l ULi ge (GIGA, Nathalie Jacobs) et l’ULB (DPP, David Vermijlen), publi e dans PNAS, montre qu une population de cellules du syst me immunitaire, les cellules T , pourrait avoir un effet important dans le cancer du col de l ut rus induit par les papillomavirus humains (HPV), la troisi me cause de d c s par cancer chez les femmes.

    Les r sultats obtenus montrent que les oncoprot ines virales peuvent induire une r organisation des sous-populations T , les faisant passer d’une fonction antitumorale une fonction pro-tumorale dans cette tumeur viro-induite.

    Tout le monde en parle.

    Noel pharma

    Le Jardin Massart-ULB est devenu le premier smart jardin en Belgique! Gr ce aux efforts conjoints de la Facult des Sciences et la Facult de Pharmacie de l ULB (en la personne du Profeseur St vigny de notre unit “Pharmacognosie, Bioanalyse et M dicaments (PBM)”), le num rique fait aujourd hui son entr e dans la collection des plantes m dicinales du Jardin Massart-ULB.





    Facult – de Pharmacie, noel pharma.#Noel #pharma

    Bienvenue sur le portail de la Facult de Pharmacie

    La Facult de Pharmacie est une Facult innovante et moderne, qui propose trois ann es de Bacheliers et deux ann es de Masters en sciences pharmaceutiques.

    Des Stages professionnels compl mentaires (1,5 mois) sont int gr s la 5 me ann e (bloc 2 du Master) : orientation officine, h pital, industrie, pharmacie clinique, analyse biologique, recherche, coop ration, etc.

    La Facult propose galement :

    Un apprentissage dynamique, sous forme de projets transdisciplinaires interprofessionnels, comme par exemple le Projet Edupharm en Master.

    Des programmes d changes Erasmus (Espagne, Italie, . ).

    Des services et des possibilit s d’acc s une plateforme analytique pour des analyses ou des formulations.

    Un dipl me d Agr gation de l’enseignement secondaire sup rieur en sciences pharmaceutiques.

    Un Certificat d’aptitude p dagogique appropri l’enseignement sup rieur en pharmacie.

    La situation d’Hamid se d t riore

    Alors qu’il aurait d j d tre lib r en ao t 2015, depuis le 30 juillet dernier, suite des violences qui ont t commises son encontre, Hamid a entam une gr ve de la faim. Son tat de sant est pr occupant. Signez la nouvelle p tition pour le soutenir.

    Noel pharma

    Franc succ s pour le Relais pour la vie 2017!

    Noel pharma

    Comme chaque ann e, ces 14 et 15 octobre, l’ULB courait en quipes dans le cadre du Relais pour la vie organis par la fondation contre le cancer, afin de rendre hommage au combat quotidien des Battants, de saluer la m moire des victimes de cette maladie mais aussi de collecter des fonds pour financer la recherche.

    L’ quipe de notre Facult s’est particuli rement distingu e. Non seulement parce qu’elle est l’ quipe facultaire a avoir r uni la somme la plus importante cette ann e. Mais surtout gr ce sa participation active qui a t applaudie par les organisateurs. Sa pr sence, tout au long du weekend, de jour (stand scientifique) comme de nuit (animation assur e par le Cercle CePha et le BePha) a t particuli rement appr ci e.

    Notre Doyen remercie Etudiant.e.s, Ancien.ne.s et Membres du personnel qui ont contribu ce succ s par leurs dons, leur aide et leur pr sence.

    Papillomavirus et cancer du col de l’ut rus: des lymphocytes impliqu s

    Noel pharma

    Une population de cellules immunitaires peu connues favorisent le cancer du col de l ut rus provoqu par le papillomavirus. Une tude men e conjointement par l ULi ge (GIGA, Nathalie Jacobs) et l’ULB (DPP, David Vermijlen), publi e dans PNAS, montre qu une population de cellules du syst me immunitaire, les cellules T , pourrait avoir un effet important dans le cancer du col de l ut rus induit par les papillomavirus humains (HPV), la troisi me cause de d c s par cancer chez les femmes.

    Les r sultats obtenus montrent que les oncoprot ines virales peuvent induire une r organisation des sous-populations T , les faisant passer d’une fonction antitumorale une fonction pro-tumorale dans cette tumeur viro-induite.

    Tout le monde en parle.

    Noel pharma

    Le Jardin Massart-ULB est devenu le premier smart jardin en Belgique! Gr ce aux efforts conjoints de la Facult des Sciences et la Facult de Pharmacie de l ULB (en la personne du Profeseur St vigny de notre unit “Pharmacognosie, Bioanalyse et M dicaments (PBM)”), le num rique fait aujourd hui son entr e dans la collection des plantes m dicinales du Jardin Massart-ULB.